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Metabolic Reprogramming in Glioma
Marie Strickland and Elizabeth A. Stoll *
Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK
Many cancers have long been thought to primarily metabolize glucose for energy
production—a phenomenon known as the Warburg Effect, after the classic studies of
Otto Warburg in the early twentieth century. Yet cancer cells also utilize other substrates,
such as amino acids and fatty acids, to produce raw materials for cellular maintenance
and energetic currency to accomplish cellular tasks. The contribution of these substrates
is increasingly appreciated in the context of glioma, the most common form of malignant
brain tumor. Multiple catabolic pathways are used for energy production within glioma
cells, and are linked in many ways to anabolic pathways supporting cellular function. For
example: glycolysis both supports energy production and provides carbon skeletons
for the synthesis of nucleic acids; meanwhile fatty acids are used both as energetic
substrates and as raw materials for lipid membranes. Furthermore, bio-energetic
pathways are connected to pro-oncogenic signaling within glioma cells. For example:
AMPK signaling links catabolism with cell cycle progression; mTOR signaling contributes
to metabolic flexibility and cancer cell survival; the electron transport chain produces
ATP and reactive oxygen species (ROS) which act as signaling molecules; Hypoxia
Inducible Factors (HIFs) mediate interactions with cells and vasculature within the tumor
environment. Mutations in the tumor suppressor p53, and the tricarboxylic acid cycle
enzymes Isocitrate Dehydrogenase 1 and 2 have been implicated in oncogenic signaling
as well as establishing metabolic phenotypes in genetically-defined subsets of malignant
glioma. These pathways critically contribute to tumor biology. The aim of this review
is two-fold. Firstly, we present the current state of knowledge regarding the metabolic
strategies employed by malignant glioma cells, including aerobic glycolysis; the pentose
phosphate pathway; one-carbon metabolism; the tricarboxylic acid cycle, which is
central to amino acid metabolism; oxidative phosphorylation; and fatty acid metabolism,
which significantly contributes to energy production in glioma cells. Secondly, we highlight
processes (including the Randle Effect, AMPK signaling, mTOR activation, etc.) which are
understood to link bio-energetic pathways with oncogenic signals, thereby allowing the
glioma cell to achieve a pro-malignant state.
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GLIOMA: AN INTRACTABLE CANCER
Glioma is the most common form of adult-onset primary malignant brain tumor, with 5 cases
per 100,000 people diagnosed each year (CBTRUS, 2009). In approximately 55% of cases, glioma
manifests as a grade IV astrocytoma (called glioblastoma, or GBM), a highly aggressive tumor.
Patients with GBM currently receive a dire prognosis, with a median survival of just over one
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year (Ohgaki and Kleihues, 2005). Patients with lower-
grade gliomas, including Grade II-III astrocytoma and
oligodendroglioma, have a better prognosis, although these
tumors do increase in grade over time, with a median survival
rate of approximately five years (Dolecek et al., 2012).
Genetically-defined subtypes of GBM have been identified
through large-scale analysis of patient tissue samples (Verhaak
et al., 2010). The Classical subtype is characterized by epidermal
growth factor receptor (EGFR) tyrosine kinase amplification,
p16/p14 deletion, and high levels of Notch protein expression;
the Mesenchymal subtype is characterized by Neurofibromatosis
1 (NF1)/Phosphatase and tensin homolog (PTEN) co-deletion,
high MET protein expression, and high levels of inflammation;
the Pro-neural subtype generally demonstrates high expression
of platelet-derived growth factor receptor (PDGFR) A as well
as mutations in the tumor suppressor p53 and the Kreb’s Cycle
enzyme isocitrate dehydrogenase 1 (IDH1); these mutations
are also common in low-grade gliomas. The Neural subtype
has transcriptional similarities to normal neurons, including
expression of neurofilament protein, synaptic proteins, and
chloride transporters, despite having a morphologically glial
appearance similar to other subtypes of GBM.
Current treatments for malignant glioma include a
combination of surgical resection, radiotherapy or radiosurgery,
and chemotherapy (typically temozolomide). There is a great
need to develop new therapies, to improve overall survival
time and quality of life for these patients. Recent efforts in
drug development for slowing glioma progression has focused
on the inhibition of growth factor receptor tyrosine kinases,
cell-surface receptors, and pro-malignancy kinase signaling
pathways. Cancer cell metabolism also provides ample scope for
the identification of new therapeutic targets. This review aims
to comprehensively summarize the current state of knowledge
regarding glioma cell metabolism, as well as the open questions
in this fast-moving field.
A NOTE ON MODEL SYSTEMS FOR
STUDYING CANCER CELL METABOLISM
IN VITRO AND IN VIVO
The field of cancer cell metabolism has exploded in the past ten
years, but why now? Recently, it has become appreciated that
classical model systems for studying malignant glioma may not
perfectly reproduce the biochemistry or physiology of human
tumors. Two critical factors have greatly impacted the recent
boom in this research area: the development of new cell culture
techniques (particularly neurospheres and serum-free adherent
primary cultures) and new animal models of malignant glioma,
including patient-derived xenograft (PDX) models, genetically-
engineered mouse (GEM) models, and syngeneic transplant
models.
Cell culture is a critical tool in our field, but care must
be taken in the process of cell isolation and maintenance.
Unfortunately, genetic profiling has undermined confidence in
the integrity of older cell lines. For example, the sub-clone
of U-87 commonly used in many labs today (U-87-MG) is
not actually derived from the original tumor cells, although it
probably is derived from a human glioblastoma (Allen et al.,
2016). Genetic profiling of the U-251 cell line and its derivatives
demonstrated that sub-clones share a common origin from
a single human glioblastoma, but have undergone significant
genetic drift. U-251 and related cells used today have lost
the common GBM characteristics observed in early-passage,
including amplification of chromosomes 3, 7, 15, and 17, and loss
of chromosomes 10, 13, and 14, although all sub-clones maintain
homozygous deletion of the p16/p14ARF locus (Torsvik et al.,
2014).
Culturing cancer cells in the presence of serum has been
shown to alter their epigenetic and biochemical characteristics,
especially leading to deletion of 18q11-23 (Masters et al., 2001),
a locus containing several protein-encoding genes that play
key roles in lipid metabolism and oxidative phosphorylation
(Huret et al., 2013). Perhaps such genetic changes may
underlie phenotypic alterations observed upon serum exposure,
including altered bio-energetic strategies and adaptation in
cellular metabolism. Culturing cells with the growth factors bFGF
and EGF, but without fetal bovine serum, is now the standard
in the field (Fael Al-Mayhani et al., 2009). Patient-derived cells
maintained under serum-free conditions in neurospheres or
laminin-attached monolayers have been shown to retain the
original characteristics of the human tumors (Lee et al., 2006;
Pollard et al., 2009) and have a more oxidative phenotype (Lin
et al., 2017).
Animal models which effectively reproduce the key
characteristics of human tumors are crucial for studying
cancer cell metabolism. Xenografts of human glioma cells
that have been implanted into the flanks of animals, rather than
orthotopically, are not growing in the brain environment with the
characteristic nutrient availability of that tissue (Huszthy et al.,
2012). Additionally, the common use of immunocompromised
mice to prevent rejection of xenografted human cells, eliminates
immune responses which are thought to play roles in driving
tumor progression (Budhu et al., 2014). Since the interactions
between immune factors, inflammatory responses and metabolic
signaling are unknown, it is difficult to judge at this time
whether these models are appropriate for investigating these key
hallmarks of cancer biology.
Since these cancer models do not reproduce the complex
interactions of glioma cells with surrounding brain tissue and
immune factors, such systems may not accurately reflect human
tumor biology. For this reason, immunocompetent murine
models of glioma which are orthotopic and do not utilize
serum-exposed cell lines are increasingly considered necessary
for testing novel therapeutics prior to clinical investigation in
patients (Oh et al., 2014). Bypassing these issues may improve
efforts to predict therapeutic response to therapies targeting
either cellular bio-energetics or immune factors in animal
models.
Moving forward, it would be best for biochemical pathways
to be investigated in glioma cells under serum-free conditions
in vitro and in a relevant biological context in vivo. Where
possible and relevant in this review, we will note the type ofmodel
system used for experimentation.
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GLYCOLYSIS AND RELATED PATHWAYS
The Dogma of Glioma Cell Metabolism:
Reliance on Aerobic Glycolysis
Many cancers, including glioma, have long been thought
to primarily metabolize glucose for energy production, a
phenomenon known as the Warburg Effect, after the first reports
of the phenomenon in sarcoma cells by Otto Warburg in 1925
(Warburg, 1925). This process refers to the incomplete, non-
oxidative metabolism of glucose even in the presence of oxygen—
thought to be characteristic of cancer cells, in comparison to
normal cells which readily undergo oxidative phosphorylation
(Warburg, 1956).
During oxidative phosphorylation glucose is taken up by
respiring cells and undergoes glycolysis; the end-product
pyruvate is then able to enter the Kreb’s (tricarboxylic acid,
or TCA) cycle (Figure 1). This produces NADH (reduced
nicotinamide adenine dinucleotide) which is fed into the electron
transport chain, yielding 36 molecules of adenosine triphosphate
(ATP) per glucose molecule. During aerobic glycolysis however,
the end product of glycolysis—pyruvate—is converted into
lactate and released into the extracellular space. This process only
yields 2 molecules of ATP per glucose molecule, and is inefficient
in supporting cellular energy demands (Vander Heiden et al.,
2009).
The advantage that the Warburg effect conveys to cancer
cells is unclear. It has been posited that ATP levels are not a
limiting factor for cancer cells (Vander Heiden et al., 2009),
since this metabolic phenotype appears prior to hypoxia (Woolf
and Scheck, 2012). It is therefore generally accepted that cancer
cells undergo aerobic glycolysis so that the NADH by-product
of lactate production can be used to fuel biomass production
and lactate can be utilized to acidify the microenvironment,
facilitating invasion (Vander Heiden et al., 2009).
While the Warburg Effect has been observed in gliomas and
other tumors (Oudard et al., 1996), it has been noted that aerobic
glycolysis does not account for the total ATP production in
many types of cancer cells—both immortalized cell lines and
primary cultures (Vander Heiden et al., 2009)—suggesting that
other substrates are being oxidized. When this hypothesis was
first formally tested in MCF-7 breast cancer cells in 2002, it
was discovered that total ATP turnover was 80% oxidative and
20% glycolytic (Guppy et al., 2002). When this hypothesis was
tested in primary-cultured human glioblastoma cells, it was
observed that cells were highly oxidative and largely unaffected
by treatment with glucose or inhibitors of glycolysis (Lin et al.,
2017). Thus, it appears that substrate oxidation can co-exist with
aerobic glycolysis and lactate release.
A further complication—alongside intracellular metabolic
complexity—is potential heterogeneity in metabolic strategies
across different cell types within the tumor. In particular,
cancer stem cells which propagate tumor growth and allow
recurrence after resection or chemotherapeutic treatment, may
exploit different metabolic strategies than other cells within the
tumor. For example, a recent study showed that glioma stem
cells (GSCs) are less glycolytic than differentiated glioma cells,
consuming lower levels of glucose and producing lower amounts
of lactate while maintaining higher ATP levels compared with
their differentiated progeny. The notorious radio-resistance of
this cell population is correlated with higher mitochondrial
reserve capacity, leading the authors to conclude that GSCs
primarily rely upon oxidative metabolic strategies and will not be
vanquished by therapies aiming to inhibit glycolysis (Vlashi et al.,
2011).
Imaging studies using radiolabelled ligands also bear out this
point in regard to malignant glioma. It has long been appreciated
that, from a diagnostic imaging perspective, glucose uptake is not
a reliable indicator for malignant gliomas. Thirty five to forty
percent of recurrent gliomas in human patients are not observed
using positron emission tomography imaging techniques based
on fluorodeoxyglucose uptake (e.g., FDG-PET), despite being
detected by contrast MRI (Belohlavek et al., 2002). These tumors
do not have higher glycolytic rates compared with ongoing
brain activity, in line with recent studies suggesting that glucose
uptake is insufficient to account for brain tumor metabolism
(Maher et al., 2012; Mashimo et al., 2014). Other radiolabelled
substrates are now being explored to visualize gliomas, such
as the PET tracer 3′-deoxy-3′[(18)F]-fluorothymidine, [(18)F]-
FLT. 18F-FLT uptake provides a higher correlation with KI67
index resected tissue compared with 18F-FDG, and has greater
predictive power with respect to tumor progression and patient
survival (Chen et al., 2005). It may prove useful to consider
other metabolic features of gliomas which could be exploited
to improve imaging strategies (Albert et al., 2016). Ultimately,
while glucose uptake is critically linked to glioma cell metabolism,
this process is not sufficient to differentiate gliomas from normal
brain or to calculate energy production (Belohlavek et al., 2002;
Maher et al., 2012; Mashimo et al., 2014).
Production of Nucleic Acids through the
Pentose Phosphate Pathway
Glioma cells have particular anabolic needs which can be supplied
by glucose uptake and shuttling. A dividing cell must continually
produce nucleotides to provide material for DNA replication,
RNA transcription, energy currency (e.g., ATP and GTP) and
the structural elements of secondary messengers (e.g., cAMP and
cGMP). To accomplish this metabolic task, glucose-6-phosphate
produced during the initial steps of glycolysis is diverted
through the pentose phosphate pathway (PPP), where it is
converted to ribose-5-phosphate (Figure 1). With the addition of
glutamine, glycine, aspartate, CO2 and tetrahydrofolate, ribose-
5-phosphate is converted into purine nucleotides, or alternatively
combined with bicarbonate, aspartate and glutamine to assemble
pyrimidines. Both purines and pyrimidines can also be produced
through salvage pathways.
The PPP appears to be particularly active in dividing cells
within glioma. Telomerase reverse transcriptase (TERT), which
is necessary for maintenance of dividing cells, is associated
with increased expression and phospho-activation of PPP
enzymes through the generation of reactive oxygen species
(ROS) (Ahmad et al., 2016). In contrast, knockdown of TERT
causes glycogen accumulation. Interestingly, heterogeneous
glioma cells, defined by their rate of cell division, appear to
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FIGURE 1 | Glycolysis and related pathways fuel biosynthesis and energy metabolism in cancer cells. This schematic shows how the glycolytic pathway
feeds into other pathways, including the Kreb’s Cycle (which fuels amino acid synthesis and provides metabolic intermediates for the electron transport chain), the
pentose phosphate pathway (PPP, which is involved in nucleic acid synthesis), and one-carbon metabolism (the folate-methionine cycle).
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have differential expression of glycolytic and PPP enzymes,
suggesting possible metabolic underpinnings for go-versus-
grow behavior (Kathagen-Buhmann et al., 2016). Specifically,
highly proliferative cells have elevated PPP enzymes and
lower expression of glycolytic enzymes, while highly migratory
cells have a reverse profile. Thus, it appears that metabolic
specialization within tumors prize nucleic acid generation in
dividing cell types. Mechanisms controlling this behavior in
glioma cells are understudied.
Transfer of One-Carbon Units through the
Folate-Methionine Cycle
Multiple reactions involving volatile carbons are handled by the
paired folate-methionine pathway, including thymidine synthesis
and the intraconversion of serine and glycine. Tetrahydrofolate,
derived from folic acid, is a versatile carbon donor; it can carry
a variety of one-carbon groups including methyls, methylenes,
and formyls, making it a highly useful cofactor in biosynthetic
reactions (Figure 1). Meanwhile S-adenosylmethionine acts
solely as a methyl donor. One-carbon metabolism may play a
critical role in cancer metabolism.
One recent study demonstrated that methionine deprivation
compromises glioma cell growth (Palanichamy et al., 2016).
This metabolic pathway is critical to the process of DNA
methylation (Mehrmohamadi et al., 2016), providing a close
working connection between cellular metabolism and epigenetic
modulation. In other cancer cell types serine supports the
production of both S-adenosylmethionine and ATP (Oliver
Maddocks et al., 2016), and is required for growth by supporting
the folate-methionine cycle (Labuschagne et al., 2014).
Glycine and serine levels increase in cultured rat glioma
cells exposed to oxygen and glucose deprivation (Fuchs et al.,
2012) and enzymes within this pathway are highly expressed
in pseudopalisading cells surrounding necrotic foci (Kim et al.,
2015). Compartmentalization of this metabolic activity into
specific geographical regions of the tumor—particularly in areas
most exposed to toxic compounds released by dying cells—
suggests the folate-methionine pathway may play an adaptive
role for the growing tumor by accommodating nearby cell death.
Currently, this pathway is highly understudied in glioma.
KREB’S CYCLE: A CENTRAL HUB FOR
CELLULAR METABOLISM
The Kreb’s Cycle, is the center of catabolic and anabolic activity
within the cell. This process takes place in the mitochondrial
matrix and is the main driver of oxidative activity, coupled to
both the electron transport chain and many anaplerotic reactions
(Figure 2).
The Kreb’s cycle can also run in reverse, with citrate being
converted to pyruvate by ATP citric lyase and pyruvate being
converted to oxaloacetate by pyruvate carboxylase. Malate
dehydrogenase and fumarase catalyze their own reverse reactions
as well; the resulting fumarate can be used to drive the urea
cycle, a coupled reaction used to dispose of excess nitrogen and
facilitate protein turnover. Also, gluconeogenesis is initiated from
the Kreb’s Cycle: phosphoenolpyruvate carboxykinase is a lyase
which catalyses the conversion of oxaloacetate to P-enolpyruvate,
a gluconeogenic precursor. The Kreb’s cycle is therefore a flexible
central provider for the catabolic and anabolic needs of the cancer
cell.
Importantly, multiple substrates can be used to drive this
critical pathway; glycolysis, beta-oxidation, and ketolysis provide
acetyl-CoA as an end product. Acetyl-CoA is then converted to
citrate by condensation with oxaloacetate (which is regenerated
by the completion of the cycle). Some studies using cultured
cell lines have suggested that glioma cells use glutamine as
a catabolic substrate, entering the Kreb’s Cycle through IDH
(Yang et al., 2009; Venneti et al., 2015). However, other
evidence, using radiolabelled glutamine and glucose in vivo
to trace the biochemical fate of these substrates in patient-
derived xenograft models, suggests the contribution of glutamine
to glioma metabolism occurs through hepatic gluconeogenesis
and glutamine itself is not metabolized within gliomas (Marin-
Valencia et al., 2012). Interestingly, glutamine and glutamate are
actually released by glioma cells, affecting the surrounding neural
tissues (Buckingham et al., 2011).
Mutations in Kreb’s Cycle enzymes are common in cancers.
In particular, IDH1 and 2 are present in over 80% of
low-grade gliomas and a subset of glioblastomas. IDH1
resides in the cytoplasm, while IDH2 is localized to the
mitochondrion; the wild-type enzymatic isoforms catalyze
the oxidative decarboxylation of isocitrate to α-ketoglutarate
while mutant IDH1 (R132H) and IDH2 (R172K) catalyze
the conversion of α-ketoglutarate into the oncometabolite 2-
hydroxyglutarate. Interestingly, the evolutionarily-distinct IDH3,
which produces NADH not NADPH, does not appear to be
mutated at any appreciable rate in glioma cells (Krell et al., 2011).
The effects of IDH1 and IDH2 mutations on α-ketoglutarate
flux and accumulation of 2-hydroxyglutarate leading to altered
intracellular signaling in glioma cells, have been extensively
reviewed elsewhere (Waitkus et al., 2015).
Indeed, several metabolic processes are altered in mutant
IDH gliomas. Patients with wild-type IDH1 and IDH2 have
higher levels of branched-chain amino acids valine, leucine,
and isoleucine, and the enzyme that initiates their catabolism
(branched-chain amino acid transaminase 1; BCAT1) (Tonjes
et al., 2013). When BCAT1 is knocked down with shRNA, glioma
cell growth is reduced in vitro and in vivo, and when treated with
gabapentin, a pharmacological inhibitor of BCAT1, glutamate
release is also attenuated.
IDHmutations not only affect amino acidmetabolism but also
lower glucose oxidation through inhibitory phosphorylation of
pyruvate dehydrogenase (PDH) (Izquierdo-Garcia et al., 2015).
In addition, IDH1 mutant glioma cells show greater flux through
pyruvate carboxylase (Izquierdo-Garcia et al., 2014) leading to
greater production of oxaloacetate. These results suggest that
IDH1 mutant glioma cells adaptively run the Kreb’s Cycle
backwards, perhaps to produce sufficient succinate to power the
electron transport chain. Reverse flux of α-ketoglutarate to acetyl-
CoA is a necessary early step in phospholipid synthesis for IDH-
wildtype glioma cells and normal astrocytes, especially under
hypoxic conditions when hypoxia-inducible factor-1α (HIF1α) is
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FIGURE 2 | The Kreb’s Cycle and oxidative phosphorylation pathways are central to cell metabolism. Acetyl CoA from many different sources can enter the
Kreb’s Cycle (also known as the citric acid cycle, or tricarboxylic acid cycle). This pathway not only drives oxidative phosphorylation by regenerating succinate, but it
provides many useful intermediates for biosynthesis. The enzyme complexes of the electron transport chain, which support oxidative phosphorylation, are shown
embedded in the inner mitochondrial membrane.
activated (Wise et al., 2011); this lipid production is attenuated in
glioma cells with mutant IDH (Chen et al., 2014). IDH1mutation
therefore not only causes 2-hydroxyglutarate build-up, but also
broad changes in metabolic strategy.
Other Kreb’s Cycle enzymes are mutated, with functional
implications, in other tumor types. Mutation or loss of fumarate
hydratase (FH) can predispose cells to oncogenic transformation
and cyst formation leading to renal cancer and renal cysts,
respectively (Adam et al., 2013). Hypermethylation and a
reliance on pyruvate carboxylation is observed reliably in
paragangliomas with succinate dehydrogenase (SDH) mutations
(Lussey-Lepoutre et al., 2015). Mutations in FH and SDH in
these cancer cells cause an accumulation of metabolites which
leak out of the mitochondrial matrix and inhibit prolyl hydralase
(PHD) enzymes, leading to apoptotic resistance and hypoxia
signaling (even under oxygen-stable conditions) (King et al.,
2006). Interestingly, inhibition of PHDs has been shown to enact
hypoxia-related signaling and pro-malignant behavior in glioma
cells (Gao et al., 2016). While mutations in FH and SDH have
not been observed in glioma, the broad and consistent alterations
to metabolic strategies yielded by various alterations in key
Kreb’s Cycle enzymes across different tumor types suggest that
much can be learned about cancer cell metabolism from studies
undertaken in other tissues.
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The Kreb’s Cycle, as a central regulator of anabolic and
catabolic metabolism in the cancer cell, is well-placed to
coordinate adaptive metabolic strategies. IDH provides a clear
example of how a single mutation in this pathway can indicate
a unique pathophysiology.
FUNCTIONALITY OF MITOCHONDRIAL
AND THE MITOCHONDRIAL ELECTRON
TRANSPORT CHAIN IN GLIOMA CELLS
Glioma cells demonstrate alterations to mitochondrial
morphology, with some cells containing healthy electron-
dense mitochondria and others exhibiting mitochondria
with extensive cristolysis; these characteristics are thought to
correlate with hypoxia-resistant and hypoxia-sensitive cell types
(Arismendi-Morillo and Castellano-Ramirez, 2008).
This finding is compatible with observations of mitochondrial
physiology. GSCs have high mitochondrial reserves compared
with differentiated cell types; inhibiting neither glycolysis nor
oxidative phosphorylation in this cell type has significant effects
on energy production (Vlashi et al., 2011). These findings suggest
possible mechanisms by which the therapy-resistant GSC may
become particularly adaptive from a metabolic standpoint.
Another way to address the question of mitochondrial
integrity and functionality is through observations on
mitochondrial enzyme expression and activity. Early studies
using C6 rat glioma cell xenografts identified lower cytochrome
C oxidase (COX, Complex IV) and SDH (Complex II) enzyme
expression in more hypoxic areas of the tumor. More recently,
one group observed significantly lower Complex II-IV activity
in anaplastic astrocytomas and lower Complex I-IV activity
in glioblastomas compared with normal brain tissue, using
dissociated cells from freshly-frozen human tumors (Feichtinger
et al., 2014). Another group, using mass spectrometry to analyse
human glioma tissue samples, observed lower expression of
some Complex I subunits but higher levels of many oxidative
enzymes including catalase (Deighton et al., 2014). Yet another
group discovered in a sample of glioma cells a T→C base-
pair substitution in the ND6 subunit of Complex I which
causes stabilization of the enzyme and resistance to rotenone
and hypoxic conditions (DeHaan et al., 2004). A somewhat
contrasting picture regarding electron transport capability in
glioma cells is emerging from the use of different techniques
across different labs.
With the former studies indicating potential dysfunction in
electron transport chain Complexes I and IV (which contain
mitochondrial-encoded subunits), it is useful to identify whether
mitochondrial DNA (mtDNA) itself is intact. Upon disuse in
highly glycolytic cells, genetic drift occurs and the mitochondrial
genome accumulates mutations, so mtDNA integrity is a good
indicator of mitochondrial enzyme function (Greaves et al.,
2014). While a number of studies have detected a high number
of mtDNA mutations which have risen de novo in glioblastomas
(Lloyd et al., 2015), a relatively limited fraction of these are
predicted or observed to be pathogenic (Vidone et al., 2015).
Indeed, experimentally mtDNA-depleted GBM cells grow at a
lower rate compared to their parental cells, and take longer to
form tumors; moreover, tumors derived from mtDNA-depleted
GBM cells recover mtDNA copy number to control levels over
the course of tumor formation (Dickinson et al., 2013). These
findings suggest that mitochondrial function may be required for
glioma initiation or progression.
Overall, these findings are somewhat conflicted regarding a
possible impairment of the respiratory chain in glioma, although
this issue may potentially be resolved by positing differences
in reliance upon oxidative phosphorylation among different cell
types within the tumor.
THE CONTRIBUTION OF FATTY ACIDS TO
GLIOMA METABOLISM
Fatty Acid Biosynthesis and Oxidation
Increasingly, it is appreciated that fatty acids can act as critical
bio-energetic substrates within the glioma cell (Figure 3). Recent
results from our lab and other groups have demonstrated that
glioma cells primarily use fatty acids as a substrate for energy
production. Specifically, human glioma cells primary-cultured
under serum-free conditions oxidize fatty acids to maintain both
respiratory and proliferative activity (Lin et al., 2017). 13C in vivo
radiolabelling studies conducted in orthotopic mouse models
of malignant glioma show that acetate contributes over half of
oxidative activity within these tumors, while glucose contributes
only a third (Maher et al., 2012; Mashimo et al., 2014).
While glioma cells clearly rely upon fatty acids for energy
production, it is not clear whether they acquire fatty acids
from the bloodstream or build these carbon chains themselves.
Fatty acids pass easily through the plasma membrane, and this
may indeed be a nutrient source in vivo, but these substrates
are not made available in cell culture. However, cells do have
access to high concentrations of glucose both in vitro and in
vivo. Glucose can be transported into the cells, converted to
fatty acids by the enzyme fatty acid synthase (FASN), then
imported into the mitochondria for beta-oxidation (a process
known as a Futile Cycle, see next section). Glioma cells contain
FASN, and indeed the expression of this enzyme increases
with tumor malignancy (Tao et al., 2013). Fatty acid synthesis
is initiated from the Kreb’s Cycle, where excess citrate is
converted to acetyl-CoA by ATP citrate lyase; the product is
then carboxylated by acyl-CoA carboxylase 1 (ACC1) tomalonyl-
CoA, which is then catalyzed by FASN to produce long chain fatty
acids, such as palmitate (Currie et al., 2013). Monounsaturated,
polyunsaturated, and highly-unsaturated fatty acids are produced
by a series of desaturase enzymes: Stearoyl-CoA desaturase and
fatty acid desaturases 1 and 2. Fatty acid synthesis has been
shown to continue under low-oxygen tension and low-nutrient
conditions (Lewis et al., 2015), a process which is activated
by HIF1α signaling. Fatty acids are shuttled into lipid droplets
upon hypoxia in order to support cell growth and survival upon
re-oxygenation (Bensaad et al., 2014).
Inhibition of either fatty acid synthesis or beta-oxidation
reduces proliferation of both glioma cells (Grube et al., 2015; Lin
et al., 2016) and normal neural stem cells (Lancaster et al., 2013;
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FIGURE 3 | Ketolysis, fatty acid biosynthesis and fatty acid oxidation. These pathways provide substrates for glioma cells to make acetyl CoA or utilize it as a
building block for lipid-based molecules.
Stoll et al., 2015). These twinned metabolic pathways provide
energy and rawmaterials for cancer cell growth, and are critically
important in glioma cell malignancy. Etomoxir, a specific and
irreversible inhibitor of carnitine palmitoyl transferase I (CPT1),
the rate-limiting step in beta-oxidation, inhibits respiration and
growth of glioma cells, and could provide a new therapeutic
option for slowing tumor growth by reducing cellular catabolic
activity (Lin et al., 2017). Likewise, orlistat, an inhibitor of FASN
which is used in the clinical treatment of obesity, may also hold
promise for use as a therapy for malignant glioma (Grube et al.,
2014).
There are five main reasons that fatty acids have been
overlooked as a metabolic substrate, mostly due to technical
considerations involved in cell culture and animal studies. Firstly,
fatty acid oxidation is simply an understudied pathway; the
role of a metabolic strategy cannot be evaluated if it is not
investigated. Secondly, drugs often used to slow glioma through
inhibition of glycolysis, such as dichloroacetate (DCA), are non-
specific (Michelakis et al., 2010); DCA reduces beta-oxidation as
well so cannot be used to parse glycolytic dependency (Bonnet
et al., 2007). Thirdly, fatty acids can cause death in cancer
cells due to detergent-like effects, especially when not bound
to albumin as is commonly the case in vivo (Leaver et al.,
2002). Fourthly, the reliance of human glioma cells on fatty
acid oxidation is abrogated after serum exposure (Lin et al.,
2016, 2017), a commonly-used culture method which alters the
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characteristics of brain-derived cancer cells (Pollard et al., 2009).
Studying cells under these conditions may therefore cause an
underestimation of oxidative activity. Finally, xenograft tumor
models in nude mice, with human glioma cells transplanted into
the flank, have often been used to evaluate glycolytic inhibitors
but these non-orthotopic transplant models do not have access
to brain vasculature and its characteristic nutrient availability
(Zhou et al., 2011). Subsequently, it will be useful to study
the contribution of beta-oxidation to total energy production
in various model systems, across cell types and during tumor
progression, and how this process is regulated in glioma.
Other Uses of Fatty Acids within the Cell
Fatty acids synthesized within the cell or obtained from
the bloodstream not only contribute to energy production
through mitochondrial and peroxisomal beta-oxidation,
thereby supplying the Kreb’s cycle and electron transport
chain. They also play many critical anabolic roles within
a cell, forming phospholipids which comprise the plasma
membrane and glycerophospholipids which act as signaling
molecules. Fatty acids generate paracrine signaling molecules
such as endocannabinoids and eicosanoids, driving synthesis of
cholesterol and other steroid hormones through the mevalonate
pathway, which is highly active in glioblastoma cells (Kambach
et al., 2017), and acting as cofactors for fatty acid binding proteins
(FABPs), which are necessary for lipid droplet formation under
hypoxic conditions (Bensaad et al., 2014). In addition, fatty
acids can facilitate post-translational modifications (e.g.,
palmitoylation) of pro-malignancy proteins. Fatty acids thus play
diverse and important roles in the function of cancer cells.
Ketolysis
Ketolysis is the process by which ketone bodies are broken
down to produce acetyl-CoA (Fukao et al., 1997). Often this
process occurs in brain tissues when blood sugar levels are
low. It has been established that cells within the brain, which
normally rely on glucose, can readily switch to oxidizing ketones
produced by the liver under necessary circumstances. It is not
clear whether ketones might be utilized within glioma cells.
Recently radiolabelled acetate has been shown to be taken up as a
metabolic substrate for glioma cells (Mashimo et al., 2014). Since
ketones can provide necessary substrates for the biosynthesis of
fatty acids and can be converted into acetyl-CoA which directly
enters the Kreb’s Cycle (Fukao et al., 1997), these substrates may
provide fuel for a developing tumor (Figure 3).
However, a ketogenic diet has been proposed as a potential
therapy for glioma to slow tumor growth and reduce seizure
frequency. It is thought that low blood sugar resulting from
this dietary intervention prevents glioma cells accessing their
preferred fuel source, glucose, and the efficacy of this dietary
intervention has been demonstrated in xenograft-transplant
models of malignant glioma (Stafford et al., 2010; Abdelwahab
et al., 2012; Woolf et al., 2015; Lussier et al., 2016), as well
as mouse models of neuroblastoma, a pediatric brain tumor
(Morscher et al., 2015). It remains to be seen whether this finding
is replicated in human patients; four clinical trials are currently
ongoing to evaluate the effects of this diet on overall survival time
and quality of life measures in human patients:
• Calorie-restricted, Ketogenic Diet and Transient Fasting
During Reirradiation for Patients With Recurrent
Glioblastoma (ERGO2), sponsored by the Johann Wolfgang
Goethe University Hospital in collaboration with TAVARLIN.
• Pilot Study of a Metabolic Nutritional Therapy for the
Management of Primary Brain Tumors (Ketones), sponsored
by Michigan State University in collaboration with Sparrow
Health System.
• Ketogenic Diet as Adjunctive Treatment in Refractory/End-
stage Glioblastoma Multiforme: a Pilot Study, sponsored by
Mid-Atlantic Epilepsy and Sleep Center in collaboration with
University of Pittsburgh.
• Ketogenic Diet With Radiation and Chemotherapy for Newly
Diagnosed Glioblastoma, sponsored by St. Joseph’s Hospital
and Medical Center Phoenix.
FUNCTIONAL LINKS BETWEEN
METABOLIC PATHWAYS
It is important to note that catabolic pathways do not exist in
isolation; they are inextricably linked to the biology of the cancer
cell (Figure 4). Several pathways in particular, which have been
identified in other cancer types, may play a role in glioma as well.
The Randle Effect: Coupling of
Beta-Oxidation and Glycolysis?
Bio-energetic pathways in glioma cells do not occur in isolation;
importantly, they are connected to each other through cross-
signaling. A case in point is the Randle Effect, a prime example of
tightly-coordinated cellular energy metabolism which provides a
mechanistic link between beta-oxidation and aerobic glycolysis.
In the 1960s and 1970s, Randle showed that NADH and
acetyl-CoA produced during beta-oxidation both inhibit the
activity of pyruvate dehydrogenase (PDH), thereby promoting
the conversion of pyruvate to lactate. Well-characterized in
diabetes, the work of Randle and his colleagues reveals that non-
oxidative glycolysis can occur alongside the oxidation of other
substrates, particularly fatty acids (Randle et al., 1963).
The activity of the PDH complex, which allows the end-
product of glycolysis to enter the Kreb’s Cycle, is modulated by
reversible phosphorylation by PDH kinase (PDK); NADH and
ATP produced in the course of beta-oxidation lead to activation
of PDK, which in turn phospho-inactivates PDC, leading to
lower rates of glucose oxidation and higher rates of lactate
release (Holness and Sugden, 2003). In this way beta-oxidation
is compatible with ongoing aerobic glycolysis, and in fact could
promote the Warburg Effect.
The Corbet-Feron Effect: A Causal Link
between Acidification and Beta-Oxidation?
A more recent study has established the Corbet-Feron Effect,
where lactate-induced acidification of the microenvironment
over a period of weeks leads to adaptation of the cancer
cell population, promoting beta-oxidation as a metabolic
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FIGURE 4 | Multiple substrates can contribute to cellular bioenergetics by providing acetyl CoA. This schematic shows an integrated view of glioma cell
metabolism, demonstrating that ketones providing acetyl CoA will fuel both energy production and biosynthesis of raw materials (e.g., nucleic acids, amino acids,
phospholipids and other molecules). The non-oxidative use of glucose by glioma cells is shown in green; particularly the Warburg Effect1 where cancer cells
undergo glycolysis that is not followed by oxidation, instead converting the end product pyruvate into lactate and releasing it into the extracellular space. Aerobic
respiratory pathways used by glioma cells are shown in blue; glioma cells appear to engage in a Futile Cycle2 (gray) where fatty acids are continuously synthesized
and oxidized in glioma cells (it has been shown that inhibiting either pathway reduces cellular proliferation and slows tumor progression). Ketolysis, shown in violet,
and fatty acid oxidation, shown in teal, provides acetyl CoA which fuels the Kreb’s Cycle and oxidative phosphorylation; acetyl CoA produced from any source
facilitates anapleurosis and biosynthesis of many molecules critical to cellular function. Metabolic intermediates, such as those produced by the Kreb’s Cycle and
oxidative phosphorylation, impinge on other cellular functions, as shown in yellow. *Interactions between enzymes that link catabolic pathways, which have been
identified in other cancers but not yet studied in glioma, are shown in red. These include: the Randle Effect3 where NADH and acetyl CoA produced during fatty
acid (FA) oxidation inhibit pyruvate dehydrogenase, thus promoting glucose’s alternative fate (release as lactate), the Corbet-Feron Effect4 where lactate-induced
acidification of the microenvironment promotes the FA oxidation phenotype via acetylation-mediated activation of mitochondrial proteins, and sirtuin-mediated
regulation of histone acetylation5.
strategy (Corbet et al., 2016). This shift is associated with
histone deacetylation in the nucleus and DNA hyper-acetylation
in the mitochondria, and is dependent upon acetylation-
mediated activation of mitochondrial proteins. This effect
was demonstrated in SiHa cervix cancer cells, FaDu pharynx
squamous cell carcinoma cells, HCT-116 andHT-29 colon cancer
cells, but was not investigated in glioblastoma cells, so it remains
to be seen whether this effect is relevant in malignant brain
tumors.
A “Futile Cycle” Can Regulate an
Anabolic-Catabolic Switch
A futile cycle occurs when a cell runs two identical metabolic
pathways simultaneously in opposite directions, with no effect
but a small net consumption of ATP. Such processes (e.g., fatty
acid biosynthesis and beta-oxidation, which both occur in the
glioma cell) may seem paradoxical. Yet futile cycles accomplish
two important tasks: Firstly, they ensure the continuous
availability of raw materials through biosynthesis (e.g., heavily
used molecules such as phospholipids), while providing a good
source of ATP and NADH through the catabolism of any excess
material; and secondly, they are thought to play a critical role
in regulating metabolic processes, as a futile cycle can induce
a bi-stable oscillatory state which is highly sensitive to small
changes in enzymatic activity and can be used to communicate
changes within the cell (Samoilov et al., 2005). Several of the
signaling pathways discussed below exert their effects through
this mechanism.
AMP-ACTIVATED PROTEIN KINASE: A
COORDINATOR OF ENERGY METABOLISM
AND CELL CYCLE PROGRESSION
Structure and Function of AMPK
AMP-activated protein kinase (AMPK) is the central energy
sensor within all mammalian cells and consists of three subunits:
the catalytic α-subunit and two regulatory β- and γ-subunits
(Hardie and Alessi, 2013). AMPK senses increased ADP and
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AMP during periods of energy stress, regulating the switch
from anabolism to catabolism in order to regain cellular energy
homeostasis (Figure 5).
The γ-subunit of AMPK contains 4 cystathione β-synthase
(CBS) motifs, which have the ability to bind ATP, AMP and
ADP in accordance with their cellular ratios (Hardie and Alessi,
2013). AMP is constitutively bound to the 4th CBS motif whilst
the 2nd remains empty, allowing the remaining two motifs to
bind ATP, AMP, and ADP. When ATP levels are high AMPK
remains inactive, however when cellular energy levels are low,
AMP and ADP compete for binding to the γ-subunit (Hardie
et al., 2012). Binding of AMP and ADP changes the morphology
of AMPK, requiring N-terminal myristylation of the β-subunit,
and promoting phosphorylation of AMPK-α at Thr172 (Oakhill
et al., 2009).
Liver kinase B1 (LKB1) is the major activator of AMPK
and constitutively phosphorylates Thr172, however high ATP
binding promotes its rapid dephosphorylation (Hardie and
Alessi, 2013). The conformational change in AMPK upon
ADP/AMP binding inhibits this dephosphorylation increasing
AMPK activation 100-fold (Hardie et al., 2012). AMP itself has
the ability to cause further allosteric activation of AMPK another
10-fold, and in this manner AMPK can respond to a variety
of changes in cellular energy levels and augment its response
accordingly (Hardie et al., 2012).
The two main substrates of AMPK are ACC and
hydroxylmethylglutaryl-CoA reductase (HMGCR), which
regulate fatty acid and cholesterol metabolism respectively
(Hardie and Pan, 2002). When activated, AMPK inhibits
ATP-consuming anabolic processes by phosphorylating ACC
and HMGCR. Through inhibiting both ACC1 and ACC2,
AMPK is able to inhibit the production of malonyl-CoA, a
precursor for fatty acid synthesis and inhibitor of CPT1, thus
alleviating the rate-limiting step of beta-oxidation (Hardie and
Pan, 2002). Additionally, AMPK activation also plays a role in
other metabolic pathways, by inhibiting mechanistic target of
rapamycin (mTOR) and activating Raptor and tumor suppressor
complex (TSC1/2) to inhibit protein and mRNA translation and
increase glycolysis by inhibiting rate-limiting enzymes (Hardie
and Pan, 2002; Hardie, 2011; Hardie et al., 2012; Hardie and
Alessi, 2013). Through these mechanisms, AMPK is able to
overcome ATP depletion and energy stress maintaining cellular
energy homeostasis.
Role of AMPK in Cancer
The role of AMPK as both a tumor suppressor and potential
oncogene has been well debated; it appears that the role of
AMPK is often dependent on metabolic status of the cell and
phosphorylation status of the protein itself. AMPK inhibits
cell cycle progression whilst also providing protection from
metabolic stress induced by chemotherapeutic agents in glioma,
fibrosarcoma, and melanoma cell lines (Vucicevic et al., 2011).
Both overexpression and ablation of AMPK can induce cell cycle
dysfunction, suggesting that AMPK has a role in both tumor
suppression and progression within transformed cells (Max
Banko et al., 2011). AMPK integrates inputs from oncogenic
FIGURE 5 | The conflicting role of AMPK in glioma as a tumor suppressor and tumor promoter. Increased AMP: ATP and ADP: ATP ratios, metabolic stress
and treatment with chemotherapy results in AMPK activation in glioma cells (Hardie and Alessi, 2013). This results in the activation of several downstream pathways
that result in both tumor suppression and growth depending on the context of AMPK activation. Primarily AMPK activates p53 transcriptional activity leading to
classical cell cycle inhibition, reducing tumor growth through p21CIP1 and p27KIP1 activation (Jones et al., 2005). AMPK activation also downregulates mTOR
signaling resulting in decreased protein synthesis and G2 block, whilst also releasing its constraint on autophagy, increasing glioma survival during chemotherapy
(Vucicevic et al., 2009; Misirkic et al., 2012). Unresolved stress over prolonged periods can also result in increased apoptosis and therefore decreased viability. By
increasing Rb phosphorylation, AMPK activation is also able to overcome cell cycle inhibition (Ríos et al., 2014).
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signaling and energy metabolism before committing the cell
to undergo division (Mukherjee et al., 2008), and its control
is further complicated by mutations in tumor suppressor and
metabolic pathways.
Role of AMPK as a Tumor Suppressor in
Glioma
Cell cycle inhibition resulting from AMPK activation can occur
at both the G1/S and G2/M phases of the cell cycle by differing
mechanisms (Guo et al., 2010, Figure 5). AMPK has the ability
to bind and phosphorylate p53 and activate TSC2, in order to
halt cell cycle progression until homeostasis is restored (Jones
et al., 2005; Vucicevic et al., 2011). AMPK also activates p21CIP1
and p27KIP1, both directly and indirectly through p53. Both these
proteins act as cyclin-dependent kinase inhibitors and prevent
Rb from releasing E2F thus preventing entry into the cell cycle
(Isakovic et al., 2007). By inhibiting fatty acid synthesis, AMPK
is able to inhibit G2/M phase progression through regulating the
biosynthesis of membrane components required for cytokinesis
(Guo et al., 2010).
Within glioma, AMPK activation has been shown to
promote apoptosis, better prognosis, and increased response to
chemotherapy depending on metabolic context (Isakovic et al.,
2007; Zadra et al., 2015). Glucose withdrawal causes more AMPK
phosphorylation and apoptosis in astrocytoma cells compared
with normal astrocytes due to inefficient mTOR signaling
(Mukherjee et al., 2008). Additionally, in low density cultures
of U-251 cells, metformin-mediated AMPK activation inhibits
proliferation at G0/G1 phase, while in substrate-limiting high-
density cultures metformin promotes apoptosis; interestingly,
primary rat astrocytes are resistant to the effects of metformin
(Isakovic et al., 2007). This serves as a prime example of
differential AMPK signaling due to substrate availability and
cellular status (Figure 5).
Through tightly regulating mTOR, AMPK moderates the
progression, prognosis and resistance of malignant gliomas
(Aldea et al., 2011; Vucicevic et al., 2011). Within serum-free
primary-cultured human GSCs, metformin-mediated activation
of AMPK and FOXO3 induces differentiation and reduces
tumourigenic capacity in vivo (Sato et al., 2012). However, this
effect was only observed during culture at non-physiological
glucose concentrations (≥17.5 mM). Resistance to therapy is a
major hurdle in overcoming brain tumor recurrence but it has
been shown that AMPK activation can enhance glioma response
to temozolomide (Zhang et al., 2010). Furthermore, metformin
treatment enhances the effects of temozolomide in vitro and in
vivo, correlating with improved therapeutic response in patients
(Aldea et al., 2011; Sesen et al., 2015).
Role of AMPK in Glioma Progression
Oncogenic events often result in AMPK activation which, if
AMPK acted solely as a tumor suppressor, would be highly
counter-productive for tumor growth (Ríos et al., 2014). AMPK
activity correlates with increased proliferation in clinical samples,
U-87-MG cells, and mouse astrocytoma models, mediating
increased Rb phosphorylation and cell cycling in vitro (Rios et al.,
2013, Figure 5). Radio- and temozolomide- resistant humanGSC
clones show upregulation of genes associated with autophagy and
lipid catabolism alongside increased AMPK phosphorylation (Ye
et al., 2013). Additionally, AMPK has also been shown to play a
role in increased glioma cell migration and survival in response
to glucose withdrawal within the U-251-MG human cell line
(Godlewski et al., 2010).
AMPK is also able to induce autophagy by downregulating
mTOR activity, inducing the recycling of cellular components
and the production of ATP during starvation. By inhibiting
cholesterol catabolism in U-251 cells, autophagy was upregulated
in an AMPK-dependent manner to protect against apoptosis
(Vucicevic et al., 2009). By inducing autophagy and inhibiting
caspase-3 and p53 mediated apoptosis, AMPK activation can
increase glioma cell viability and has helped establish a role for
AMPK in tumor growth and decreased patient survival (Rios
et al., 2013; Liu et al., 2014, Figure 5).
AMPK as a Putative Futile Cycle Regulator
The contradictory roles of AMPKmay be resolved by considering
how a cycling cell achieves metabolic homeostasis. DNA
replication and cytokinesis undertaken during the process of
cell division require much energy, yet the mechanisms by which
glioma cells couple catabolic activity to cell cycle progression are
not well understood. AMPK and its family members, as nutrient-
sensing effector proteins, are well-placed to act as regulators of
a futile cycle to accomplish this task. An increased AMP/ATP
ratio activates AMPK, which inhibits biosynthetic processes
and activates beta-oxidation by inhibiting ACC (Hardie and
Pan, 2002; Hardie et al., 2012). AMPK simultaneously acts to
inhibit cell cycle progression by activating tumor suppressor
proteins (Jones et al., 2005; Liang et al., 2007). Once the cell
has enough energy, AMPK is no longer activated and the
activated protein is degraded, allowing release from the cell cycle
checkpoint. The process of mitosis then presumably depletes
energy stores allowing AMPK to be activated again (Figure 6).
Interestingly, knockdown and overexpression of this kinase cause
the same effect in cells: halting of the cell cycle resulting in
aneuploidy (Max Banko et al., 2011). A carefully-regulated,
cyclical pattern of AMPK activity—and functional downstream
effector molecules—may be required for cycling cancer cells to
function properly.
MAMMALIAN TARGET-OF-RAPAMYCIN: A
KEY TO GLIOMA CELL RESILIENCY
Structure and Function of mTOR
mTOR integrates signaling from growth factor pathways with
cellular energy and nutrient levels, co-ordinating this activity
with biosynthetic machinery and cell cycle machinery (Sarbassov
and Sabatini, 2005; Duzgun et al., 2016). Control of protein
synthesis and cell cycle entry by mTOR is mediated through the
mTOR Complex 1 (mTORC1) and the adaptor protein Raptor,
while metabolic effects of mTOR occur through association with
the mTORC2 complex with the adaptor-protein Rictor (Akhavan
et al., 2010; Masui et al., 2013, Figure 7).
mTOR acts downstream of many tumor suppressor and
oncogenic pathways, which tightly regulate its activity under
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FIGURE 6 | The dual role of AMPK activity in maintaining energy
homeostasis and ensuring nutrient sufficiency for cell cycle
progression. Upon activation by decreased ATP availability, AMPK acts to
inhibit energy consuming pathways such as cholesterol and fatty acid
synthesis (Hardie and Pan, 2002), whilst also increasing the activity of cell
cycle inhibitors p27 and p53 (Isakovic et al., 2007). This tumor suppression
acts to restore energy homeostasis by inhibiting cell cycle progression,
resulting in decreased AMPK activity and a switch from catabolism to
anabolism for completion of the cell cycle. AMPK thereby acts to maintain
energy homeostasis and ensure nutrient sufficiency for cell cycle progression.
normal circumstances. However, loss of tumor suppressors
such as p53 or oncogenic activity which converges on PI3K
(phosphatidylinositol 3-kinase) can augment mTOR activity,
resulting in glioma development (Cancer GenomeAtlas Research
Network, 2008; Akhavan et al., 2010; Levine and Puzio-Kuter,
2010; Duzgun et al., 2016).
mTOR Controls Protein Synthesis through
mTORC1
The TSC1/2 complex is the major upstream regulator of mTOR
through inactivating Ras-homolog enriched in brain (RHEB)
GTPase activity. Upon mitogenic signaling the TSC1/2 complex
is stabilized, allowing RHEB to freely activate mTORC1 (Duzgun
et al., 2016). Active mTORC1 then phosphorylates S6K1 at
Thr389 and 4E-BP1 at Ser65 to initiate protein translation
and ribosome biogenesis, respectively (Dennis et al., 2001,
Figure 8A).
AMPK is a well-known regulator of mTOR. AMPK
destabilizes the TSC1/2 complex, allowing TSC2 to bind
RHEB stimulating its GTPase activity and inhibiting its ability
to activate mTORC1 (Vucicevic et al., 2011). Interaction
with AMPK allows mTORC1 to sense energy levels and
p53 status, however it has recently been hypothesized that
mTORC1 activity may also be directly influenced by ATP
(Dennis et al., 2001; Levine and Puzio-Kuter, 2010). Low amino
acid levels can attenuate mTORC1 activity by inhibiting Rag
GTPases bound to lysosomes, thereby inhibiting mTORC1
recruitment and activation by RHEB (Laplante and Sabatini,
2012). In this manner mTOR regulates anabolic processes
by inducing protein synthesis in response to substrate levels
(Figure 8A).
mTOR as a Regulator of the Warburg
Effect in Glioma
Although mTORC1 controls protein synthesis and cell cycle
entry, the metabolic effects of mTOR activation are regulated
by mTORC2. In serum-supplemented U-87 cells, mTORC2 acts
upstream of c-Myc, another critical metabolic regulator which
induces the Warburg effect (Masui et al., 2013; Figure 8B).
mTORC2 controls c-Myc by inhibiting FoxO1 and FOX03,
through phosphorylation of PKCα and inhibition of class IIa
histone deacetylases which phosphorylate and acetylate FoxO
(Masui et al., 2013, 2015). This allows transcription of glycolytic
pathway genes, upregulation of glucose transporters (GLUT1/3)
and increased lactate production (LDHA) in U-87 cells (Masui
et al., 2013; Clark et al., 2016). Akt-expressing cells are
also able to induce glycolysis through direct phosphorylation
of FoxO1/3, relieving the blockade on c-Myc signaling and
facilitating glycolysis (Yang et al., 2009; Masui et al., 2015;
Figure 8B).
Akt and mTORC2 signaling confer glucose addiction within
glioma cells both in vitro and in vivo (Yang et al., 2009;
Tanaka et al., 2015), and without mTORC2 activity U-87
cells cannot sustain their proliferation in glucose (Masui
et al., 2013). Therefore, impairments in glucose availability
can be devastating for glioma survival. Glioma cells upregulate
glutamine metabolism as a compensatory mechanism to sustain
flux through the Kreb’s cycle, due to the ability of glucose
withdrawal to stimulate glutamate dehydrogenase activity (Yang
et al., 2009). This upregulation also aids in protecting SF-188
and U-87 cells against Akt and mTOR inhibition, by relieving
the suppression of glutamate dehydrogenase and glutaminase
by Akt and inducing α-KG-dependent anaplerosis (Yang et al.,
2009; Tanaka et al., 2015). Therefore, dual inhibition of mTOR
and glutaminase has proved to be effective in immunodeficient
subcutaneous xenografts of U-87 cells (Tanaka et al., 2015).
AMPK activation has also been shown to protect against glucose
withdrawal in Akt-expressing cells, by reducing the cellular
ability to induce beta-oxidation (Buzzai et al., 2005).
Role of mTOR in Resistance of Glioma to
Therapy
Persistently activated PI3K/Akt/mTOR axis signaling is
associated with the development of cancer (Cancer Genome
Atlas Research Network, 2008, Figure 8C). For maximal Akt
signaling and proliferation in cancer cells, Akt is phosphorylated
by both PI3K induced kinases at Thr308 and by mTORC2
at Ser473 (Akhavan et al., 2010). Interestingly, mTORC2
activation of PKCα can propagate mTORC1 signaling through
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FIGURE 7 | Components of the mTORC1 and mTORC2 signaling complexes. Both the mTORC1 and mTORC2 complexes contain mTOR, MLST8, and
DEPTOR. However, their major differences lie in the co-binding of Raptor to the mTORC1 complex and Rictor to the mTORC2 complex, in addition to their other
binding partners including PRAS40 and PROTOR1/2 and SIN1 respectively (Laplante and Sabatini, 2012).
Akt activation (Sarbassov et al., 2005; Fan et al., 2009). Due to
this mTORC2 is an essential component for tumor growth in
response to enhanced EGFR signal flux through PI3K in glioma
(Read et al., 2009), conferring resistance to EGFR inhibitors
(Stommel et al., 2007).
mTOR has been shown to mediate at least some of the
effects of concurrent loss of NF1 and PTEN (Verhaak et al.,
2010, Figure 8C). Loss of NF1 and p53, is sufficient to achieve
gliomagenesis in an mTOR-dependent process, where inhibition
of mTOR reduces NF1-mediated progression in mouse models
of optic glioma (Galvao et al., 2014; Kaul et al., 2015).
Meanwhile, cells with wild-type PTEN have reduced mTORC2
activation through Rictor Thr1135 phosphorylation; mutation or
depletion of PTEN prevents this inactivation, allowing mTORC2
activation and reduced cell cycle arrest (Bhattacharya et al., 2016,
Figure 8A).
Sustained mTORC2 signaling, due to augmented p53,
constitutive EGFRvIII signaling, and NF1/PTEN co-deletion can
confer resistance to a variety of drugs used to treat glioma.
PI3K and Akt inhibitors and Rapamycin are commonly used to
block the PI3K/Akt/mTOR axis, however rapamycin-insensitive
and sustained mTORC2 signaling imparts survival in U-87 cells
(Masui et al., 2013). Although PI3K and Akt inhibition would
be expected to deplete c-Myc levels, mTORC2 increases FoxO
acetylation as a compensatory mechanism to modulate c-Myc
and promote GBM survival (Masui et al., 2013). Due to this
signaling complexity mTORC2 has been highlighted as a major
regulator of GBM growth and drug resistance (Masui et al., 2015).
As mTORC2 knockdown suppresses the induction of glycolysis
in response to PI3K and Akt inhibitors, it has been proposed that
their combination with dual mTORC1/2 inhibitors will promote
glioma cell death and tumor regression (Masui et al., 2013).
P53 MUTATIONS AFFECT NOT ONLY CELL
CYCLE CHECKPOINTS BUT ALSO
CELLULAR BIO-ENERGETICS
Due to the interaction between energy metabolism and
proliferation, it is unsurprising that proteins known to control
the cell cycle also have a profound effect onmetabolism (and vice-
versa).Within glioma p53 has a varied role, retaining its wild-type
conformation in most primary glioblastomas and acquiring gain-
of-function mutations in the pro-neural glioblastoma subtype
and during lower-grade glioma progression (Guo et al., 2012;
Wanka et al., 2012a). p53 is widely known as a tumor suppressor,
acting upstream of many oncogenic nodes. p53 also has the
effect of restricting aerobic glycolysis and promoting oxidative
phosphorylation, while loss of p53 function contribute to the
Warburg effect (Levine and Puzio-Kuter, 2010).
p53 promotes responses to extrinsic and intrinsic stimuli
dependent on the type, severity and persistence of stress
(Vousden and Prives, 2009). Whilst wild-type p53 expression
is associated with decreased proliferation due to inhibition
of cyclin-dependent kinases, overexpression of regulatory
mechanisms such as MDM2 control p53-dependent growth
in glioma (Reifenberger et al., 1993; Suh et al., 2012).
MicroRNA-25 and -32 are repressed by p53-dependent
activities as part of a negative feedback loop in U-87
cells, however their suppression also alleviates the block
on MDM2 activity which ubiquitinates and degrades p53
(Xirodimas et al., 2001; Suh et al., 2012). Expression of
miR-25 and -32 in U-87 cells with functional p53 inhibits
their growth in vivo, signifying the importance of this
autoregulatory feedback loop in GBM proliferation (Suh
et al., 2012).
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FIGURE 8 | (A) The role of mTOR in protein synthesis. AMPK is a well-known regulator of mTOR activity (Vucicevic et al., 2011). Upon activation AMPK destabilizes
the Tumor Suppressor 1/2 (TSC1/2) complex, allowing TSC2 to freely bind Ras-homolog enriched in brain (RHEB) and inhibit mTORC1 signaling (Laplante and
Sabatini, 2012). This means that energy consuming processes such as protein translation and ribsome biogenesis are inhibited during periods of energy stress. As
well as acting through AMPK, ATP has recently also been shown to be able to directly activate mTORC1 signaling (Dennis et al., 2001). (B) The role of mTOR in
energy metabolism. mTORC2 metabolic reprogramming downstream of PI3K/Akt is a critical regulator of the Warburg effect and glucose dependence in glioma cells
(Masui et al., 2015). By relieving FoxO1/3 constraint on c-Myc signaling, mTORC2 increases Glucose Transproter 1 and 3 expression (GLUT1/3) as well as lactate
dehydrogenase activity, encouraging aerobic glycolysis (Masui et al., 2013). Simultaneously, through c-Myc activity mTORC2 also inhibits glutamate dehydrogenase
(GDH) activity required for glutaminolysis, regulating a metabolic switch from oxidative phosphorylation fuelled by the Kreb’s cycle to aerobic glycolysis (Yang et al.,
2009). mTORC2 signaling therefore causes glioma cells to become “addicted” to aerobic glycolysis, making them particularly vulnerable to glucose depletion. (C) The
role of mTOR in stem cell maintenance. Oncogenic activity which converges on PI3K can activate mTOR signaling (Sarbassov et al., 2005). mTORC1 and mTORC2
activity results in the activation of several transcription factors, including OCT4 and NOTCH and c-Myc respectively, ensuring stem cell maintainence (Masui et al.,
2013). c-Myc can also be activated directly by Akt signaling and PKCα signaling downstream of mTORC2 to induce stem cell transformation (Fan et al., 2009).
Additionally, whilst mTORC2 activity forms part of a feed-forward system, phosphorylating Akt, mTORC1 activity downregulates PI3K activity by downregulating
PDGFR (Akhavan et al., 2010; Sarbassov et al., 2005).
Induction of Oxidative Metabolism by p53
By inhibiting key oncogenic pathways that promote aerobic
glycolysis as discussed in previous sections, p53 is able to
constrict glycolytic respiration both indirectly and through
its direct interaction with glycolytic pathway components
(Deberardinis et al., 2008, Figure 9A). p53 represses the
transcription of GLUT1/4 transporters and ChREBP leading
to decreased glycolysis in colorectal cancer cell lines (Dang,
1999; Tong et al., 2009). Whereas, the p53 product TIGAR,
often overexpressed in glioblastomas, protects against
glycolytic adaptation by reducing the expression and activity of
Phosphofructokinase-1 and fructose biphosphatase in multiple
cancer types, including GBM (Bensaad et al., 2006; Wanka et al.,
2012b).
Functional p53 increases expression of glutaminase 2 (GLS2)
under stress in HTB-15 human glioblastoma cells (Hu et al.,
2010). This serves to increase oxidative metabolism and ATP
generation, by catalyzing the conversion of glutamine to
glutamate and increasing α-KG levels (Hu et al., 2010). This
metabolic effect is also seen in freshly isolated human GBM stem
cells (Michelakis et al., 2010). Additionally, increased glutamate
availability as a precursor for glutathione (GSH) helps to protect
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FIGURE 9 | (A) Functional p53 control of cell growth and oxidative metabolism. p53 plays a role in its own regulation by diminishing the inhibition of MDM2 which
mediates p53 ubiquitination, through a feedback loop involving miR-25 and -32 (Suh et al., 2012). p53 also has a role in inhibiting the activity of oncogenic pathways,
including mTOR and PI3K/Akt, halting cell cycle progression whilst DNA is repaired (Budanov and Karin, 2008). This cell cycle blockade can be alleviated by MDM2
(Reifenberger et al., 1993). This also alleviates the glycolytic switch inferred by the pathways. Additionally, p53 also has its own roles in diminishing glycolysis both
directly and indirectly through TIGAR transcription (Bensaad et al., 2006). (B) Differential response of p53 to different forms of damage. Activation of p53 due to DNA
(Continued)
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FIGURE 9 | Continued
damage (shown in green), results in the suppression of phosphoglycerate mutase (PGM) causing inhibition of the glycerate reduction. This process allows activation of
the non-oxidative arm of the PPP and production of R5P for DNA repair, instead of channeling glycolytic intermediates through the glycolytic pathway (Kondoh et al.,
2005; Deberardinis et al., 2008; Levine and Puzio-Kuter, 2010). Additionally, activation of p53 by oxidative damage (shown in blue) inhibits the degradation of
G6P-dehydrogenase (G6PD), stimulating the oxidative PPP phase and NADPH production to counter-act ROS and oxidation (Jiang et al., 2011). These pathways
provide protection from extensive DNA and oxidative damage in cancer cells expressing functional p53. However, under conditions where p53 has been activated in
response to other stimuli such as energy deprivation (shown in orange), p53 can inhibit these pathways to free-up glycolytic intermediates for pyruvate formation and
Kreb’s cycle entry (Boros et al., 1997; Christofk et al., 2008).
against oxidative stress (Hu et al., 2010; Michelakis et al.,
2010). Currently the impact of wild-type and gain-of-function
p53 mutations on rates of oxidative metabolism in GBM is
relatively understudied. However, in other cancer cell types p53-
mediated transcription of hexokinase 2 catalyzing the first step
of glycolysis and the production of tetrameric PKM2 converting
glucose to pyruvate, result in greater oxidative metabolism
(Mathupala et al., 1997; Christofk et al., 2008, Figure 9B). p53
also supports the expression of PTEN, influencing the switch
from aerobic glycolysis to oxidative metabolism by inhibiting the
PI3K/Akt/mTOR pathway (Stambolic et al., 2001). Therefore, it is
expected that p53 mutations reduce oxidative metabolism, given
our current understanding of p53 function; gain-of-function
mutations may drive an oxidative metabolic phenotype.
AMPK and p53-dependent signaling act in concert to halt
cell cycle progression whilst restoring energy homeostasis (Jones
et al., 2005). Metformin, which acts to stimulate AMPK activity,
causes synthetic lethality in colon carcinoma cells with p53
mutations highlighting the close interaction between these
proteins (Buzzai et al., 2007). p53 plays a role in increasing
mitochondrial complex activity due to AMPK activation by
enhancing the transcription of COX assembly protein 2
(SCO2) (Matoba et al., 2006; Deberardinis et al., 2008). SCO2
in combination with SCO1, forms COX acting as the last
enzyme within the electron transport chain, increasing oxygen
consumption and ATP generation (Matoba et al., 2006). To
increase flux into the Kreb’s cycle, p53 increases GLS2 expression,
in opposition to c-Myc which decreases Kreb’s cycle activity by
enhancing GLS1 expression (Hu et al., 2010; Suzuki et al., 2010).
Within glioblastoma cells p53 induction results in increased
GLS2 under oxidative stress but not oxygen or nutrient starvation
(Hu et al., 2010). However, basal p53 activity also results in
2.5-3-fold increased GLS2 transcription, maintaining glutamate
and α-ketoglutarate levels (Hu et al., 2010). In contrast, during
nutrient deprivation malate dehydrogenase 1 interacts with
p53 to modulate its transcriptional targets within glioma cells
to maintain energy homeostasis (Lee et al., 2009). Therefore,
cancer cells without functional p53 are particularly sensitive
to nutrient deprivation, diminishing the scope for engaging
catabolic pathways such as autophagy and beta-oxidation in
glioma (Buzzai et al., 2007; Munoz-Pinedo et al., 2012).
By interacting with pathways such as PI3K and mTOR,
p53 is also able to limit HIF complex stabilization, resulting
vascularization and migration (Budanov and Karin, 2008).
Additionally, p53 is also able to maintain ROS homeostasis
limiting the effect of these molecules on cell signaling dynamics
(Budanov et al., 2004). p53 activation mediates ROS levels
by inducing Sestrins1-4 and regulating p21, increasing ROS
detoxification and Nrf2 antioxidant capabilities respectively
(Mathupala et al., 1997; Budanov et al., 2004, Figure 9B). The
induction of Sestrins 1 and 2 also aids in stimulating AMPK
activity, as part of a constitutive feedback mechanism for p53
induction under oxidative stress (Budanov and Karin, 2008).
Through increasing GLS2 expression, p53 is also able to increase
de novo GSH production and maintain GSH/GSSG (GSH
disulphide) ratios in response to oxidative stress in glioblastoma
cells by increasing GSH pre-cursors (Hu et al., 2010; Suzuki et al.,
2010). Due to this increased resistance to oxidative stress, human
glioma cells with functional p53 also show greater resistance to
gamma-radiation, by reducing the toxic production of ceramide
and resulting apoptotic induction (Hara et al., 2004, Figure 9B).
Suppression of p53 in glioblastoma cells enhances the effects of
hypoxia and susceptibility to hypoxia-induced apoptosis (Wanka
et al., 2012a). A recent study highlighted increased protection
from moderate hypoxia (1% O2) correlates with p53 induction
of SCO2, which is necessary for complete respiratory chain
function in human glioma (Wanka et al., 2012a). This helps to
maintain oxidative phosphorylation and resistance to hypoxia
after p53 ablation, however this protective effect is not seen
under profound hypoxia (0.1% O2) (Wanka et al., 2012a). In
this manner p53 may provide a significant survival advantage for
glioma cells, potentially accounting for wild-type p53 retention in
primary gliomas. SCO2 deficiency reduces the number of islets of
viable cells in necrotic areas of colon carcinoma in vivo, however
this viability is retained in p53 expressing tumors conferring a
unique survival advantage (Wanka et al., 2012a).
Role of p53 in Response of Glioma Cells to
Therapy
During chemotherapy p53 also provides some protective effects
by inducing the transcription of genes involved in melavonate
pathway, alleviating the brake on cholesterol biosynthesis (Mo
and Elson, 2004). p53 induces the expression of several proteins
involved in melavonate production such as HMGCR and LDLR
(low-density lipoprotein receptor), which are upregulated at
basal levels in GBM cells compared to normal astrocytes (Laezza
et al., 2015). This may represent another pathway by which
functional p53 may be able to overcome proliferative defects,
as cholesterol is required for DNA synthesis and proliferation.
However, loss of p53-dependent control of LDLR and another
melavonate pathway element, RabGGTA, often accompanies
transformation (Laezza et al., 2015). Whilst this represents a
problem for maintaining proliferation by reducing total cellular
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cholesterol pools, loss of p53 control is overcome by endogenous
cholesterol synthesis (Laezza et al., 2015).
Wild-type p53 in U-87 cells reduces recovery in response to
ionizing radiation, whereas mutant p53 in T98 cells demonstrate
robust proliferation and reduced induction of senescence (Quick
and Gewirtz, 2006). The presence of functional p53 in U-87 cells
enhances temozolomide response by inducing apoptosis upon
prolonged G2-M arrest (Hirose et al., 2001a,b). Whilst glioma
cells expressing functional p53 show both G1 and G2/M blocks
to a limited degree, p53 null cells demonstrate a prominent
G2/M block which plays a role in radio-resistance (Tsuboi et al.,
2007). This may also explain why p53 is depleted in secondary
lesions; natural selection may be at play, favoring the clonal
expansion of p53-mutated cells. Induction of wild-type but
not mutant p53 reduces angiogenic activity of the malignant
glioma cell line LN-Z308 (Van Meir et al., 1994). Surprisingly,
sustained impairments of functional mitochondrial metabolism
in neural progenitor cells can also lead to p53 genetic inactivation
through increased ROS production and resulting damage toDNA
(Bartesaghi et al., 2015). Although this is a relatively new concept,
it may help to explain p53 loss during glioma progression,
whereby mitochondrial dysfunction potentially damages the cell,
conferring protection against radiotherapy.
PEROXISOME
PROLIFERATOR-ACTIVATOR RECEPTORS
ARE CENTRAL REGULATORS OF GENE
TRANSCRIPTION AND OXIDATIVE
METABOLISM
Peroxisome proliferator-activated receptor proteins (PPARs) are
nuclear receptors; the three subtypes (PPARα, PPARβ, and
PPARγ) exert different effects on cellular behavior, although
broadly do so by impinging on metabolic gene transcription
(Figure 10). PPARs are activated by various signaling pathways,
FIGURE 10 | PPAR signaling pathways influence metabolic capacity, growth, and survival. There are three subtypes of peroxisome proliferator-activated
receptor proteins (PPARs). PPARs are nuclear hormone receptors that are activated primarily by eicosanoids, unsaturated fatty acids, NSAIDS, and retinoic acid. Their
activation status is also influenced by cAMP second messenger cascades and MAP kinase signaling activated by G-protein-coupled receptors (GPCRs) and growth
factor receptor (GFR)-activated signaling. Upon heterodimerization with retinoic acid receptors (RXRs) and association with hydrophobic ligands, PPARs translocate to
the nucleus. There, the complexes activate transcription of metabolic genes. PPARα agonism disrupts HIF1α-mediated transcriptional activation of PKM2, thereby
reducing glycolysis; PPARα has also been implicated in tumor suppression and apoptotic initiation through various signaling pathways. PPARγ enhances
mitochondrial biogenesis, fatty acid oxidation, and insulin-mediated glucose transport into cells; PPARγ is also anti-inflammatory, preventing the activation of STAT1,
AP1, and NFκB. In many contexts, non-ligand-activation of PPAR induces transcriptional repression. The effects of PPARβ signaling in glioma are not known.
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including cAMP second messenger cascades downstream of G-
protein-coupled receptors and growth factor receptor-activated
MAP kinase signaling pathways, thus well-placed to link
extracellular factor-induced signaling pathways with cellular
metabolic activity. PPARs bind to hydrophobic ligands including
eicosanoids, unsaturated fatty acids and retinoic acid, and
interact with retinoic acid receptors and cofactors including
PGC1α to form transcription factor complexes (Tontonoz and
Spiegelman, 2008). Upon activation, PPARs translocate to the
nucleus and bind to PPAR response elements. Although PPARα
and PPARγ bind to the same cofactors, they appear to have
differential effects on gene transcription in glioma cells; the role
of PPARβ in glioma has not been characterized.
PPAR-Alpha
PPARα expression is lower in high-grade gliomas compared with
normal brain tissue; signifying worse prognosis in GBM patients.
PPARα overexpression inhibits growth, invasion, and aerobic
glycolysis in glioma cells (Shi et al., 2016). Fenofibrate, a PPARα
agonist which drives transcriptional activity, has been shown to
reduce cancer cell growth in U-87-MG glioma cells and in other
cancers (Saidi et al., 2006; Panigrahy et al., 2008; Han D. F. et al.,
2015). Fenofibrate lowers lipid content in the bloodstream; it also
directly inhibits glycolysis in glioma cells by disrupting binding of
the NF-κB-HIF1a complex to the PKM2 promoter (Han D. et al.,
2015). This drug also causes structural damage to mitochondria
and inhibition of Complex I, leading to activation of the AMPK-
mTOR pathway, promoting autophagy (Wilk et al., 2015; Han D.
et al., 2015). The broad-ranging metabolic effects of fenofibrate
on glioma cells are associated with lowered cell growth, due to
FOX01/p27-induced G0/G1 arrest, and increased apoptotic cell
death caused by FOXO3a-activated transcriptional activation of
the apoptotic initiator protein Bim (Wilk et al., 2012; Han D. F.
et al., 2015).
PPAR-Gamma
The nuclear receptor PPARγ is activated by hydrophobic
molecules including fatty acids (Tontonoz and Spiegelman,
2008). Once activated by a ligand, the PPARγ complex binds
to response element sequences throughout the genome and
modulates transcription of its target genes, many of which
enhance mitochondrial function and beta-oxidation (Itoh et al.,
2008). Over-representation of PPARγ polymorphism H449H is
observed in sporadic cases of glioblastoma compared with the
normal population (Zhou et al., 2000); however the functional
significance of this is not known. PPARγ agonists cause
upregulation of the glutamate transporter, reducing extracellular
glutamate levels and excitotoxicity in the vicinity of in U-
87 and U-251 cells (Ching et al., 2015). In addition, agonists
of PPARγ reduce tumor growth in xenografted LN-229 cells
(Grommes et al., 2013), however it should be noted that
antagonism of PPARγ conversely reduces tumor growth in Sonic
hedgehog-driven mouse models of medulloblastoma (Bhatia
et al., 2012). PPARγ agonists have therefore been proposed
as novel anti-neoplastic agents for the treatment of glioma,
although currently these drugs have not been evaluated in serum-
free glioma cell cultures or direct-to-xenograft animal models
(Ellis and Kurian, 2014). A Phase II clinical trial evaluating
treatment with pioglitazone, a relatively specific PPARγ agonist,
in combination with the chemotherapeutic temozolomide and
the COX2 inhibitor rofecoxib, did not demonstrate improved
prognosis, and individual patient responses did not correspond
to protein expression levels of COX2 or PPARγ (Hau et al., 2007).
More studies are needed to evaluate the biological and functional
roles of PPARs in glioma.
Sirtuins
Another group of regulatory proteins which acts independently
and in partnership with PPAR nuclear receptors are the sirtuins,
which are Class III histone deacetylases. Sirtuins provide a direct
connection between catabolic activity and histone deacetylation
in cancer cells. High NAD+ levels activate Sirtuins, which
in turn repress expression of key tumor suppressor genes
while increasing expression of telomerase (Zhang et al., 2014).
These proteins also modulate a number of signaling pathways
to influence cellular metabolism and oncogenic potential. In
particular, Sirtuin-1 has been shown to inhibit HIF activation,
activate mitochondrial biogenesis through PPARγ-cofactor 1α
(PGC1α), drive lipid metabolism through sterol regulatory
element-binding protein factors, mediate inflammatory signaling
through NF-kB, and inhibit p53-mediated apoptosis through
inhibitory deacetylation in other cell contexts (Lavu et al.,
2008; Kitada et al., 2013; Gonzalez Herrera et al., 2015). This
family of proteins have not been well-studied in the context of
glioma, although tantalizing initial evidence suggests that Sirtuin-
1 is actually required for gliomagenesis (Lee et al., 2015) and
inhibition of Sirtuin-1 through miR-22 (which also targets EGFR
and matrix metalloprotease 9) slows the growth and invasiveness
of U-87 and U-251 glioma cells (Chen et al., 2016). Further
studies are needed to identify the roles of Sirtuin-1 and other
sirtuins in the epigenetic modulation of glioma cells, and how
these effects might be mediated.
REACTIVE OXYGEN SPECIES AND REDOX
HOMEOSTASIS
Production of Reactive Oxygen Species
(ROS) in Glioma Cells
The electron transport chain couples the transfer of charge
across the inner mitochondrial membrane with the production
of ATP. The leakage of ROS and protons from Complexes I-IV of
the electron transport chain represents a self-regulating system
to reduce oxidative stress, whereby ROS themselves induce
proton leak and decrease ROS generation (Brookes, 2005). Redox
homeostasis involves the Nrf2-dependent antioxidant system
which is important for inhibiting differentiation and promoting
drug resistance in GSCs (Akhavan et al., 2010; Cardaci and
Ciriolo, 2012). GSH acts as an electron acceptor to reduce ROS
during its conversion to GSSG (Levine and Puzio-Kuter, 2010).
GSH is then reformed from GSSG by GSH reductase which
reduces NADPH to form NADP+ (reformed during the PPP and
Kreb’s cycle) (Levine and Puzio-Kuter, 2010; Wanka et al., 2012b,
Figure 11A). Oxidative stress is also avoided via ROS scavengers:
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FIGURE 11 | (A) Reactive oxygen species (ROS) maintenance by redox homeostasis. Oxidative phosphorylation and endoplasmic reticulum (ER) activity both result in
the formation of ROS (Salazar-Ramiro et al., 2016). These ROS can be neutralized by antioxidants, under the transcriptional control of Nrf2, the master regulator of
ROS homeostasis (Cardaci and Ciriolo, 2012). Additionally, proton leak in the mitochondria also helps to neutralize ROS through a self-regulating system (Brookes,
2005). Another system to regulate ROS levels, acts through the glutathione (GSH) system which neutralizes ROS upon conversion into glutathione disulphide (GSSG)
(Levine and Puzio-Kuter, 2010). Within cells, GSH levels are maintained by production of NADPH from the PPP and Kreb’s cycle which maintain GSH reductase
activity (Levine and Puzio-Kuter, 2010). (B) ROS cycle of AMPK activation and resolution. Increased ROS levels result in oxidative DNA damage and the activation of
the DNA damage response pathway by ataxia-telangiectasia mutated (ATM) recognition (Alexander and Walker, 2011). This stimulates LKB1 activity, and increased
phosphorylation and stimulation of AMPK. As a result AMPK inhibits NADPH consuming pathways such as FAS and activates catabolic NADPH-producing pathways
such as FAO, which acts through the GSH/GSSG antioxidant system to neutralize ROS and restrain further oxidative damage (Jeon et al., 2012). (C) Oncogenic
factors contributing to ROS production. Two common mutations in secondary gliomas include the mutation of isocitrate dehydrogenase (IDH) and p53 pathways
(Cuperlovic-Culf et al., 2012). Through their downstream activities, i.e., IDH reducing isocitrate into α-KG and p53-mediated transcription of TIGAR, these proteins aid
in maintaining NADPH levels and subsequent ROS neutralization (Wanka et al., 2012b; Klink et al., 2016). However, upon mutation these pathways are inhibited
resulting in a loss of NADPH, increased ROS and a higher rate of oxidative damage within glioma cells.
glutathione peroxidase (GPx), superoxide dismutases (SODs),
catalase, thioredoxin, and peroxiredoxin (Jin et al., 2015).
Although cancer cells rely heavily on glycolysis and
glutaminolysis to reduce ROS production, oxidative
phosphorylation does contribute to the ATP pool (Zhang
et al., 2015; Ozcan and Cakir, 2016). In the rapidly proliferating
SF-188 pediatric glioblastoma cell line there is a shift away from
glycolysis toward oxidative glutaminemetabolism represented by
increased oxygen consumption and increased ROS (Pike Winer
and Wu, 2014); likewise adult glioblastoma cells are also highly
oxidative (Lin et al., 2017). Additionally endoplasmic reticulum
activity involving protein and lipid formation, contributes 25%
of cellular ROS production in glioma cells (Salazar-Ramiro
et al., 2016). Increased ROS levels contribute to a variety of
tumorigenic processes inducing proliferation, genetic instability
and evasion from senescence (Levine and Puzio-Kuter, 2010).
Cancer cells show an increased tolerance for oxidative stress
whereby moderate ROS levels promote proliferation and
differentiation, whilst excessive ROS exposure causes oxidative
damage and induces apoptosis (Jin et al., 2015; Rinaldi et al.,
2016).
Role of AMPK in Redox Homeostasis
The LKB1/AMPK axis represents another system by which
cells control redox homeostasis (Figure 11B). Upon ROS-
mediated DNA damage, LKB1 associates with ATM kinase
and AMPK, resulting in phosphorylation of ACC (Alexander
and Walker, 2011; Jeon et al., 2012). By regulating the switch
from anabolism to catabolism, AMPK stimulates NADPH
production through beta-oxidation limiting oxidative stress
(Jeon et al., 2012). LKB1 is also able to restrict oxidative damage
through its AMPK-independent interaction with Cdc42 and
decreased phosphorylation of p38-MAPK reducing anabolic ROS
production (Xu et al., 2015).
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Mutations in the tumor suppressor LKB1 limit AMPK
activity and the production of NADPH through catabolic
processes; unrestrained ROS can promote tumor growth by
boosting oncogenic signal transduction, genetic instability and
glioma growth in vivo (Jeon et al., 2012). ROS are also
able to inhibit LKB1-mediated activation of AMPK, alleviating
mTOR inhibition and promoting entry into the cell-cycle and
glioma proliferation in vitro (Jiang et al., 2014). Downstream
of AMPK, PGC-1α controls transcription of antioxidative
proteins alongside mitochondrial biogenesis, highlighting the
tight control of ROS in response to increased mitochondrial
respiration (Hartel et al., 2016). This system aids glioma cells in
evading apoptosis due to prolonged ROS exposure.
Role of ROS in Glioma Development
IDH plays a role in producing antioxidants, as well as promoting
oxidative respiration and oxygen-sensitive signaling transduction
(Cuperlovic-Culf et al., 2012, Figure 11C). Under normal
circumstances IDH activity reduces NADP+ whilst catalyzing
the oxidative decarboxylation of isocitrate to α-ketoglutarate,
however IDH mutants consume NADPH during the synthesis
of the oncometabolite 2-hydroxyglutarate, thereby decreasing
antioxidant defense (Cuperlovic-Culf et al., 2012; Lewis et al.,
2014; Klink et al., 2016). The central role of a functioning Kreb’s
cycle in maintaining redox balance is highlighted by conversion
of glutamate into α-KG by glutamate dehydrogenase and the
maintenance of NADPH and GSH/GSSG ratios (Jin et al., 2015).
TIGAR is also involved in protecting glioma cells frommetabolic
and oxidative stress (Figure 11C). Through enhancing the
energy yield from glucose and promoting oxidative respiration,
TIGAR inhibits ROS production through enhancing NADPH
and GSH:GSSG ratio as a result of enhanced PPP flux (Wanka
et al., 2012b).
EGFR activation or constitutive EGFR signaling induce ROS
production in glioma cell lines (Salazar-Ramiro et al., 2016).
Additionally, glioma cells exhibiting loss of the tumor suppressor
p53 also display higher levels of ROS and oxidative stress due to
the loss of SOD2, GPX1, and ALDH4A1, which form part of the
antioxidant system (Macedo et al., 2012). ROS can also directly
phosphorylate signaling proteins and increase flux through
PI3K/Akt and MAPK/ERK to potentiate oncogenic signaling
(Boonstra and Post, 2004; Rinaldi et al., 2016, Figure 12).
Interestingly, increased ROS in GSCs is associated with reduced
self-renewal, increased cycling, and reduced viability through
activation of p38 under oxidative stress (Yuan et al., 2015).
However, under non-stressed conditions ROS-activated JNK and
p38 cooperate with ERK to support proliferation and increase
tumorigenic activity in glioma (Benhar et al., 2002; Yuan et al.,
2015).
Redox status also regulates responses to nutrient deprivation.
Oxidizing agents which reduce the NADPH/NADP+ ratio,
and increase ROS, can increase mTORC1 signaling and confer
resistance to nutrient deprivation and inhibition of the PI3K/Akt
pathway (Sarbassov and Sabatini, 2005). Reducing agents
act in the opposite manner to mimic cellular responses to
nutrient deprivation, slowing proliferation. Additionally, ROS
FIGURE 12 | The downstream effects of ROS signaling in glioma cells. Activation of AMPK as a result of oxidative damage induced by ROS, has both tumor
suppressive and promotive effects within glioma cells, through AMPK signaling (Alexander and Walker, 2011). Additionally ROS aids in oncogenic signaling resulting in
the activation of pathways involved in metastasis, invasion, proliferation, and resistance (Boonstra and Post, 2004). ROS mediates the formation of invadopedia
involved in metastasis and inflammatory signaling through NF-kB to promote matrix degradation and invasion (Zhang et al., 2015). Additionally PI3K/Akt and
MAPK/ERK pathways are also augmented resulting in increased proliferation, as well as increasing c-Jun and c-Fos formation of the activator protein-1 (AP-1)
transcription factor involved in proliferation (Benhar et al., 2002; Waris and Ahsan, 2006). Finally, ROS are also involved in S6K1 activation which acts to induce
autophagy providing chemotherapeutic resistance (Sarbassov and Sabatini, 2005).
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can also directly phosphorylate c-Jun and c-Fos, resulting in
activation of activator protein-1 transcription factor, glioma
growth and proliferation (Waris and Ahsan, 2006). In glioma
the metabolic effects of ROS involve DNA damage responses
and the Jnk pathway which modulates glucose uptake, ATP
levels and hexokinase-2 and pyruvate kinase activity. Whilst
damage activates antioxidative defense by activating the PPP
in glioma, Jnk activation downregulates hexokinase-2 and
PKM2 obstructing glycolysis, forcing reliance on oxidative
phosphorylation and sensitizing glioma cells to oxidative stress
(Dixit et al., 2014).
Despite increased ROS levels being of benefit to
tumorigenesis, oncogenic signaling through c-Src, Ras, and
Erk1/2 also amplifies the antioxidative system in order to
maintain redox homeostasis (Salazar-Ramiro et al., 2016,
Figure 12). By coupling redox maintenance with mitochondrial
biogenesis signaling, glucose metabolism, and growth factor
signaling, cancer cells are able to avoid oxidative stress (Zhang
et al., 2015). Redox metabolism is coupled closely with the
cell cycle, forming a reductive environment to minimize
damage during DNA synthesis and anaerobic glycolysis, and an
oxidative environment during mitosis driving biogenesis and
proliferation (Zhang et al., 2015). This reductive state during
DNA synthesis is associated with reduced functionality and ROS-
dependent metastasis by boosting formation of invadopodia
during oxidative phases, correlating with glioma stemness
characteristics (Zhang et al., 2015). Metastasis is also affected
by ROS-mediated activation of ERK and the redox-sensitive
IκK/NF-κB pathway, promoting tissue digestion through
metalloproteinase expression and glioma invasion (Chiu et al.,
2010; Yuan et al., 2015).
HYPOXIA INDUCIBLE FACTORS AND THE
TUMOR MICROENVIRONMENT
Microenvironmental Factors in Glioma
Progression
Glioma progression is characterized by the appearance of
extensive regions of hypoxia within the tumormicroenvironment
(Kucharzewska et al., 2015). The formation of a hypoxic niche
is associated with tumor aggressiveness, drug resistance, and
enrichment of GSCs which recapitulate the tumor following
resection and therapy (Mimeault and Batra, 2013; Ye et al., 2013).
Hypoxia has many effects, depending upon the extent of
oxygen deprivation and exposure time (Figure 13). Hypoxia
causes: activation of Hypoxia Inducible Factors (HIF; the subject
of this section), facilitation of adaptive metabolism (such as
formation of lipid droplets), release of vascular endothelial
growth factor (which influences the surrounding tissue to
support neo-angiogenesis), and death (if resultant signaling and
nutrient restoration does not promote survival). In fact it has
been proposed that varying oxygen levels within a tumor make
metabolic heterogeneity inevitable (Strickaert et al., 2016).
Regulation of Hypoxia Inducible Factors
HIFs are primarily regulated by HIF prolyl-hydroxylases (PHDs)
which hydroxylate Pro402 and Pro564 on HIF-1α. This allows
for the recruitment of Von Hippel-Lindau ubiquitin E3 ligase
which marks HIF-1α for proteasomal degradation (Semenza,
2010) (Figure 14A). As PHDs require oxygen for their activity,
HIF activation is dependent on oxygen; under low-oxygen
tension HIF-1α is not degraded and mediates metabolic
reprogramming toward a glycolytic phenotype (Semenza, 2010).
Factors inhibiting HIF-1 hydroxylate HIF-1α at Asp802, blocking
the binding of p300 and CREB-binding protein and HIF-1
transcriptional activity, acting as another regulatory pathway
(Semenza, 2010). In this manner HIF is able respond to
alterations in the tumor microenvironment and mediate
metabolic reprogramming.
Downstream of its regulation HIF-1α acts in concert with
HIF-1β as a transcription factor to coordinate metabolic changes
to preserve oxygen and induce angiogenesis to increase oxygen
tension. HIF-1 regulates a shift from oxidative metabolism
to anaerobic glycolysis when oxygen levels are depleted
(Kucharzewska et al., 2015). By increasing the expression of
GLUT1/3, Hexokinase-2, PDK1 and LDHA, HIF-1 induces
glycolysis, whilst simultaneously upregulating PDK1 to reduce
flux through the Kreb’s cycle and electron transport chain,
to maintain ATP levels in the absence of oxygen (Semenza,
2010; Kucharzewska et al., 2015). PDK1 also has a role in
inhibiting PDH, to further amplify the cellular response to
hypoxia (Kucharzewska et al., 2015).
HIFs drive metabolic reprogramming and decrease cell
cycling in response to acute periods of hypoxia (Neurath et al.,
2006; Kathagen et al., 2013). However, unresolved hypoxia or
constitutive HIF signaling in cancer escalates glioma initiation,
development, and migration (Kathagen et al., 2013).
Constitutive HIF Signaling in Glioma
Hypoxia often arises concurrently with increased ROS/NOS
production, which can act indirectly to stabilize HIF complexes
(Chandel et al., 2000, Figure 14B). ROS/NOS oxidize the
catalytic iron center of PHD and FIH and inhibit their activity
to stabilize the HIF-1 complex (Semenza, 2010). Reduced FoxO
phosphorylation/acetylation caused by oncogenic signaling also
plays a role in stabilizing HIF-1 in ROS-dependent manner.
FoxO3 transcriptional activity attenuates ROS levels, reducing
HIF-1α stabilization in normal cells, however as FoxO3 activity is
often downregulated due to oncogenic signaling, HIF-1 is further
stabilized by increased ROS tolerance in glioma (Ferber et al.,
2012). HIF signaling also results in enhanced antioxidant levels in
glioma, which may act as a modulatory mechanism to maintain
redox homeostasis and inhibit hypoxic death (Kucharzewska
et al., 2015). Additionally, TIGAR also helps to protect cells
against hypoxic death by controlling HIF-induced ROS levels
(Wanka et al., 2012b).
HIF-1α expression is often increased due to oncogenic
signaling. Increased HIF-1 expression requires activation of the
PI3K/Akt/mTOR and MAPK/ERK pathways, and HIF-1 can
further activate itself through these pathways (Qiang et al., 2012;
Mimeault and Batra, 2013). Ras, a central node in controlling
growth factor signaling, can increase expression of HIF-1α
through augmented mTOR signaling and increased translation
of HIF-1α (Semenza, 2010; Cairns et al., 2011). Activation of
PDGFR in glioma also supports HIF-1 activity (Semenza, 2010).
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FIGURE 13 | The broad-ranging effects of hypoxia in promoting tumorigenesis in glioma, and protection from immediate ill effects of re-oxygenation.
Acute periods of hypoxia result in the up-regulation of many glycolytic genes resulting in the release of lactate and an acidic microenvironment, which is conducive for
localized invasion. Hypoxia is also accompanied by mitochondrial dysfunction as a result of this metabolic adaptation, resulting in excess accumulation of ROS and
apoptosis. Under conditions of moderate hypoxia, GBM cells downregulate fatty acid, and cholesterol biosynthesis pathways and primarily rely on increased fatty acid
uptake to meet their nutrient requirements, through upregulation of fatty acid binding proteins particularly FABP7, resulting in the formation of lipid droplets in a time-
and oxygen-dependent manner (Bensaad et al., 2014). Restricted oxygen availability and nutrient deprivation are often accompanied by poor vascularisation, causing
extensive increases in apoptosis (Lewis et al., 2015). However, under these conditions some glioma cells have been shown to upregulate sterol regulatory
element-binding protein (SREBP) to maintain fatty acid and cholesterol metabolism by disrupting the mevalonate pathway (Lewis et al., 2015). The accumulation of
lipids in GBM helps to maintain viability upon re-oxygenation after angiogenesis, providing an alternative source for ATP production and protecting against ROS
accumulation (Bensaad et al., 2014).
PKM2 in its tetrameric form is a target of HIF-1 metabolic
remodeling to increase ATP production through glycolysis (de
Wit et al., 2016). PKM2 also has a dimeric form in cancer, which
has a nuclear localization sequence allowing PKM2 to act as a
co-transcription factor and kinase stimulating HIF-1α expression
and activity (de Wit et al., 2016).
Downstream signaling from insulin-like growth factor (IGF1)
through Ras to HIF-1α upregulates mRNA encoding IGFBP2,
thus autoregulating HIF by decreasing IGF1 signaling (Feldser
et al., 1999; Sinha et al., 2011). IGFBP2 is often upregulated in
GBM, promoting tumor development, progression, and invasion
(Lin et al., 2015). Through modeling it was shown that IGFBP2
plays an integral role in sustaining HIF-1α signaling in an
oxygen-independent manner due to its negative effect on IGF1
signaling (Lin et al., 2015).
Role of HIFs in Glioma Progression
By upregulating glucose import and metabolism, oxygen-
independent HIF regulation can induce glycolysis even in the
presence of oxygen, contributing to the Warburg effect. Ras-
mediated HIF-1α signaling downregulates PDH activity and
mitochondrial respiration, also increasing tumorigenic potential
by inducing aerobic glycolysis (Prabhu et al., 2015, Figure 14C).
Hypoxic signaling in glioma also increases AMPK-mediated
catabolism of proteins, in keeping with the enhanced autophagy
observed in glioma and its role in conferring resistance to
nutrient deprivation and therapy (Mimeault and Batra, 2013;
Clark et al., 2016). By recapitulating reductive metabolism in the
form of glycolysis and glutaminolysis constitutive activation of
HIF-1 in cancer can contribute to cell growth (Lemaire et al.,
2015).
HIF-1α has previously been reported to inhibit c-Myc activity
within renal cell carcinoma to support the switch to glycolysis
whilst minimizing proliferation, however in the opposite manner
HIF-2α stimulated c-Myc/Max dimerization within these cells
resulting in tumorigenesis (Gordan et al., 2007). Within glioma
cells hypoxia upregulates serine hydroxymethyltransferase
(SHMT2) due to increased HIF-1α and c-Myc activity. Increased
SHMT2 activity in GBM can limit PKM2 activity, increasing
PPP flux and decreasing Kreb’s cycle intermediates and oxygen
consumption (Kim et al., 2015). This mechanism provides
selected glioma cells under hypoxia a survival advantage by
increasing NADPH through mitochondrial serine degradation
and protecting against ROS-induced hypoxic death (Ye
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FIGURE 14 | (A) Hypoxia-inducible factor (HIF) regulation within normal cells. There are two main avenues governing HIF-1α within normal cells, involving the
factor-inhibiting hypoxia-1 (FIH-1) and Von Hippel-Lindau (VHL) proteins (Semenza, 2010). The activity of these proteins is regulated by oxygen levels, whereby FIH-1
hydroxylates HIF-1α at Asp802 blocking its transcriptional activity, whereas VHL activity is reliant on prolyl-hydroxylase (PHD) to hydroxylate Pro402 and everPro564
under oxygenated conditions, marking HIF for degradation by VHL (Semenza, 2010). However, when oxygen levels are low HIF is not marked for degradation and is
therefore its transcriptional activity is unrestrained. (B) Effects of constitutive HIF activation in glioma. The constitutive activation of HIF under normal oxygen tension is
known as pseudo-hypoxia. Oncogenic signaling in cancer cells acts to stabilize HIF under normoxia primarily through the activation of PI3K/Akt and MAPK/ERK
pathways (Qiang et al., 2012; Mimeault and Batra, 2013). In turn, as a result of HIF transcription STAT3 is upregulated resulting in further activation of these oncogenic
pathways (Mimeault and Batra, 2013; Qiang et al., 2012). HIF stabilization often arises in concert with ROS production, which acts to stabilize HIFs by oxidizing the
catalytic iron center of PHD and FIH-1, limiting HIF degradation (Chandel et al., 2000; Semenza, 2010). Reduced FoxO3 activity as a result of oncogenic signaling and
HIF transcription also acts to increase ROS production as part of a feed-forward mechanism (Ferber et al., 2012). (C) Role of HIF in maintaining ATP production under
hypoxia. Upon stabilization the HIF-1 complex acts in concert with the CREB-binding protein (CBP)/p300 co-activator to alter the transcription of multiple genes
involved in metabolism (Semenza, 2010). Through increasing the transcription of GLUT1/3, HK2, PDK1, and LDHA, HIF-1 increases glucose uptake and glycolysis
whilst inhibiting the Kreb’s cycle and oxidative metabolism (Semenza, 2010; Kucharzewska et al., 2015). Additionally, HIF-1 transcription also inhibits PKM2 activity to
limiting flux through the Kreb’s cycle and oxidative metabolism (Kim et al., 2015).
et al., 2014). Increased SHMT2 is a common feature of
pseudopalisading cells surrounding necrotic areas in GBM
demarcating zones of angiogenesis and hypoxia for rapid
re-oxygenation (Mimeault and Batra, 2013; Kim et al., 2015).
The feed-forward mechanisms supporting constitutive HIF
signaling maintain the development of an invasive, metastatic
and lethal phenotype in glioma (Semenza, 2010, Figure 13).
Hypoxia within the glioma microenvironment results in the
induction of neural stem cell markers, such as Oct3/4, Sox2, and
Nestin in synergy with EMT molecules such as VEGF, which
correlate with tumor aggressiveness (Qiang et al., 2012; Mimeault
and Batra, 2013). By promoting stem cell maintenance and
angiogenesis, hypoxia inhibits neural stem cell differentiation
and promotes increased vasculature, key events in cancer
progression and metastasis (Qiang et al., 2012).
Lactate production, due to HIF metabolic remodeling, also
has a role in creating a favorable environment for glioma
invasion (Figure 14). Lactate causes a decrease in extracellular
pH forming an acidic microenvironment, which promotes the
death of surrounding tissue, ECM degradation and subsequent
localized migration (Kathagen et al., 2013; Mimeault and Batra,
2013). Ninety three percent of hypoxia areas show co-expression
of HIF and HSP90 as a result of acidosis, further increasing the
ability of GSCs to withstand nutrient deprivation and therapeutic
interventions by further modulating metabolism (Filatova et al.,
2016).
AUTOPHAGY: YOU ARE WHAT YOU EAT
Autophagy Is Dependent upon
Mitochondrial Dynamics
In times of stress, the cancer cell may wholly or partially digest
itself in a process called autophagy. In some cases, this process
can lead to cell death; indeed this is a primary mechanism
by which temozolomide acts to kill glioma cells (Lefranc
et al., 2007). However, limited autophagy can allow survival
of glioma stem cells under nutrient-deprived conditions (Sun
et al., 2016), and down-regulation of these supportive autophagic
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processes can sensitize glioma cells to chemotherapeutics and
promote apoptosis (Isakovic et al., 2017). High levels of pro-
autophagy genes are associated with worse glioma patient
survival, particularly in patients with the mesenchymal subtype
of glioblastoma (Galavotti et al., 2013).
Autophagy is tightly controlled by mitochondrial dynamics,
the process by which mitochondria undergo fusion and
fission (Figure 15). Mitochondrial fusion acts as an acute
compensatory mechanism to deal with cellular stress, by
increasing mitochondrial DNA copy number (Chen et al., 2010),
boosting expression of electron transport chain complexes,
allowing rapid diffusion of metabolic intermediates (Karbowski
and Youle, 2003; Twig et al., 2008) and increasing ATP
production rates (Tondera et al., 2009). Fusion thereby enables a
cell to manage an increased energy demand, particularly in times
of stress, thus preventing the need for autophagy or apoptosis
(Gomes et al., 2011; Rambold et al., 2011).
Mitochondrial fission, in contrast, reduces oxidative capacity
and increases genetic drift of mitochondrial-encoded subunits
of the electron transport chain (Taguchi et al., 2007). After
mitochondrial membrane depolarization, any weak organelles
which do not recover normal potential can undergo two
fates: initiation of apoptosis or selective autophagy of the
dysfunctional mitochondrion (mitophagy). The benefits of
mitophagy are primarily: to remove damaged organelles which
cannot contribute to cellular respiration, to prevent Bax/Bak
channel formation, to reduce the quantity of caspases and other
signaling factors which initiate apoptosis, and to recycle the
material within the autophagosome for protein synthesis and
membrane fabrication. Thus, mitophagy provides a powerful
route to cellular survival, especially in times of nutrient
deprivation.
Autophagy and Underlying Mitochondrial
Dynamics Influence Cell Cycle Progression
Mitochondrial dynamics play a critical role in cancer cells, as
dysregulated fusion and fission have been implicated in tumor
initiation and cancer activity (Loureiro et al., 2013). Interestingly,
mitochondrial dynamics act as critical cell cycle control
mechanisms with highly-motile organelles arranging themselves
to ensure mitochondrial homogenization and segregation
during cell division (Antico Arciuch et al., 2012; Mishra and
Chan, 2014). Mitochondrial fusion is required for maintaining
mitochondrial membrane potential and for permitting entry into
S-phase, meanwhile mitochondrial fission is required at later
stages, notably to impart a mitochondrial population to each
daughter cell during cytokinesis (Taguchi et al., 2007; Schieke
et al., 2008; Yang et al., 2015). Although specific mechanisms
linking mitochondrial fusion and fission factors to cell cycle
regulatory proteins have not been characterized in glioma cells,
FIGURE 15 | Mitochondrial dynamics are linked with cell cycle, respiratory capacity, and cell survival. Mitochondrial dynamics are regulated in concert with
the cell cycle and coordinate metabolic activity; fusion facilitates high rates of oxidation while fission permits initiation of apoptosis or adoption of an autophagy-based
survival strategy.
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mitochondrial dynamics do appear to be tightly tied to cell
cycle progression, providing a potentially critical process linking
cellular bio-energetics with growth. Indeed knockdown of the
mitochondrial fission factor Drp1 in patient-derived cells reduces
growth in vitro (Xie et al., 2015); impairments or loss of
Drp1 have been associated with lower autophagic flux in other
cancer cell types (Thomas and Jacobson, 2012). Intriguingly,
one group has shown that stimulation of autophagy impairs
invasion in glioma cell lines (Catalano et al., 2015), while another
group has demonstrated that down-regulation of autophagy
impairs invasion in primary human glioma cells (Galavotti et al.,
2013). Further work in this area is necessary to resolve these
contradictory findings.
The process of autophagy is influenced by multiple metabolic
signaling pathways including AMPK, mTOR, and other
factors (Westermann, 2012). Under normal conditions, PARP1
and AMPK form a complex in the nucleus of glioma cells;
upon nutrient starvation this complex is disrupted, leading
to nuclear export and initiation of autophagy (Rodriguez-
Vargas et al., 2016). ROS signaling, often in the presence of
hypoxia, activates PTEN which inhibits the PI3 kinase/mTOR
pathway, thus promoting autophagic flux (Errafiy et al.,
2013). Interestingly Dram1-mediated localization of the
autophagy protein Sequestome 1 appears to work independently
of the mTOR pathway to initiate autophagy (Galavotti
et al., 2013). In addition, rapamycin-induced autophagy
appears to be independent of mTOR signaling; siRNA-based
knockdown of mTOR sensitizes both PTEN-wildtype and
PTEN-mutant cells to rapamycin-induced cell death in a
synergistic manner (Iwamaru et al., 2006), demonstrating
the complexity of signaling crosstalk related to autophagy
control. These processes likely work in concert to coordinate
the formation of the autophagosome and guide autophagy.
Autophagy remains a promising target for drug development in
neuro-oncology.
THE FUTURE OF GLIOMA CELL
METABOLISM
Recent years have yielded exciting findings in the field of
cancer cell metabolism, suggesting that Warburg is only a
small part of the larger story. While glioma cells do partially
metabolize glucose, releasing lactate into the extracellular space,
other substrates are being oxidized. Yet the questions remain:
What fraction of ATP is produced from glycolysis, and what
fraction from oxidation? What substrates are preferentially
oxidized? How easily can a glioma cell change its metabolic
strategy upon exposure to hypoxia, nutrient deprivation, or
acidic environment? Do different cells within the tumor have
different metabolic strategies or preferred metabolic substrates?
Do gliomas with different oncogenic driver mutations (e.g., in
p53, NF1, or IDH) have differentmetabolic strategies or preferred
metabolic substrates? How do glioma cells balance anabolic and
catabolic needs to support growth and invasion? What is the best
substrate to use as a radioligand for PET imaging in these tumors?
And, of course, can these bio-energetic pathways be targeted
pharmacologically to slow growth and invasion of glioma? The
stage is set to enter a new era in glioma biology, by augmenting
our knowledge of genetics and intracellular signaling with a more
comprehensive understanding of cellular bio-energetics.
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